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„Gehe nicht, wohin der Weg gehen mag, 
sondern dorthin, wo kein Weg ist, 
und hinterlasse eine Spur.“  
(Jean Paul) 
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Summary 
 II
CoQ10 acts as an obligatory cofactor in the electron transport in the respiratory chain.  
Additionally, CoQ10 is required for the biosynthesis of pyrimidine nucleotides and the 
function of uncoupling proteins (UCPs). The reduced form of CoQ10 (Q10H2) serves 
as a potent antioxidant of lipid membranes. More recently, CoQ10 has been identified 
as a modulator of gene expression in vitro. This established function of CoQ10 was 
investigated in the present thesis on the molecular, cellular and physiological level by 
the use of bioinformatics and cell culture models as well as animal and human 
studies.  
 
Based on text mining analysis, a functional connection of CoQ10-sensitive genes was 
performed. Through signalling pathways of G-protein coupled receptors, JAK/STAT 
and integrin, 17 genes were functionally connected as previously published in Caco-2 
cells. Moreover, promoter regions of genes related to inflammation revealed binding 
sites for the pivotal inflammatory transcription factor NFκB. To evaluate the data from 
the in silico analysis in an experimental context, monocytic cells were either treated 
with the oxidized (Q10) or reduced (Q10H2) form of CoQ10. Subsequently, the LPS-
induced release of NFκB-dependent cytokines and chemokines was determined in 
cell-free supernatants. Finally, both for Q10- and Q10H2-incubated cells reduced 
secretion levels of the pro-inflammatory mediators TNFα, RANTES and MIP-1α have 
been observed.  
 
On the basis of the in vitro results, indicating slight differences in the anti-
inflammatory properties of Q10 and Q10H2, redox-dependent gene expression patterns 
were hypothesized. To test this assumption in vivo, a genome-wide expression 
profiling was performed in various tissues (liver, kidney, heart and brain) of SAMP1 
mice. Animals were either supplemented with Q10 or Q10H2 (500 mg/kg BW/d) for 6 (6 
M) or 14 (14 M) months, respectively. In doing so, liver seemed to be the main target 
tissue of CoQ10 intervention, followed by kidney, heart and brain. In comparison to 
Q10, Q10H2 supplementation was more effective to increase total CoQ10 levels in liver 
tissues of SAMP1 mice. Evaluation of the array data also indicated a stronger impact 
on gene expression by Q10H2 when compared to Q10. Gene expression analysis in 
the liver of 14 M SAMP1 mice identified 11 Q10H2-sensitive genes primarily involved 
in cholesterol and lipid metabolism as well as inflammation and cell differentiation. 
Results from text mining revealed a functional connection of these genes in PPARα 
signalling pathways. Interestingly, these genes were not regulated in liver tissues of 
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Q10-treated mice. Moreover, a key regulator gene in cholesterol metabolism, CYP51, 
was significantly down-regulated in the Q10H2-treated group, but became up-
regulated in Q10-supplemented animals. Hence, the redox sensitivity of the identified 
genes might be a possible explanation for the observed differences in liver 
cholesterol levels of Q10H2- and Q10-supplemented mice.  
 
For further verification of the results obtained from in vitro experiments, 53 healthy 
male volunteers were supplemented with Q10H2 (150 mg/d) for 2 weeks. Based on 
microarray data and stringent selection criteria, 7 Q10H2-sensitive genes related to 
inflammatory and apoptotic processes were identified in isolated monocytes. For the 
identified Q10H2-sensitive genes, text mining analysis revealed a functional 
connection in NFκB and PPAR signalling pathways. As PPARs are known key 
players in lipid metabolism and cell differentiation, in addition to the transcriptional 
effects, a putative impact on physiological parameters such as LDL cholesterol and 
blood cell count was determined. Thereby, Q10H2 supplementation showed a 
significant reduction of LDL serum cholesterol levels. Additionally, due to the 
significant differences in the count of maturated red blood cells (erythrocytes) and 
immature reticulocytes, effects on cell differentiation processes were hypothesized.  
 
In summary, the results from the in silico, in vitro and in vivo studies show anti-
inflammatory properties of Q10H2 as well as a regulatory role in cholesterol 
metabolism and cell differentiation processes. These effects could be explained, at 
least in part, by a modulatory impact of Q10H2 on redox-sensitive NFκB/PPARα 
dependent gene expression.  
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Coenzym Q10 (CoQ10) ist ein essentieller Cofaktor bei der Übertragung von 
Elektronen in der mitochondrialen Atmungskette. CoQ10 ist außerdem notwendig für 
die Pyrimidinbiosynthese und für die Funktion von Entkopplungsproteinen. Die 
reduzierte Form von CoQ10 (Q10H2) wirkt zusätzlich als Antioxidanz in biologischen 
Membranen. Aus zurückliegenden in-vitro-Untersuchungen kann auch ein Einfluss 
von CoQ10 auf Ebene der Genexpression geltend gemacht werden. Diese neue 
Funktion von CoQ10 wurde in dieser Arbeit mit Hilfe von bioinformatischen Ansätzen, 
Zellkulturexperimenten sowie Tier- und Humanstudien auf molekularer, zellulärer und 
physiologischer Ebene analysiert.  
 
Mit Hilfe einer Text-Mining-Methode wurde eine funktionelle Verknüpfung von CoQ10-
sensitiven Genen abgebildet. Unter Einbezug von publizierten Genexpressionsdaten 
aus humanen Caco-2-Zellen wurden 17 Gene identifiziert, die durch gemeinsame 
Signalkaskadewege (G-Protein-gekoppelter Rezeptor, JAK/STAT und Integrin) 
miteinander verbunden sind. Zusätzlich wurden in den Promotoren von einigen 
CoQ10-sensitiven Genen Bindungsstellen für den zentralen proinflammatorischen 
Transkriptionsfaktor NFκB identifiziert. Zur Validierung dieser in-silico-Analyse auf 
experimenteller Ebene wurden monozytäre Zellen mit oxidiertem (Q10) oder 
reduziertem (Q10H2) CoQ10 präinkubiert. Anschließend wurde die LPS-induzierte 
Freisetzung von NFκB-abhängigen Zytokinen und Chemokinen im Zellkulturmedium 
untersucht. Die Q10H2- und Q10-Inkubation führte zu einer signifikant verminderten 
Sekretion der proinflammatorischen Marker TNFα, RANTES und MIP-1α. 
 
Auf Grundlage der in-vitro-Untersuchungen, die unterschiedliche 
antiinflammatorische Potentiale zwischen Q10H2 und Q10 erkennen lassen, wurde 
zusätzlich auf redox-sensitive Genexpressionsmuster geschlossen. Um dieser 
Annahme unter in-vivo-Bedingungen nachzugehen, wurde ein genomweites 
Expressionsprofil in Leber, Niere, Herz und Gehirn von SAMP1-Mäusen erstellt. 
Hierzu wurden die Tiere entweder mit Q10H2 oder Q10 (500 mg/kg BW/d) bzw. einer 
entsprechenden Kontrolldiät über einen Zeitraum von 6 (6 M) bzw. 14 (14 M) 
Monaten supplementiert. Hinsichtlich der untersuchten Gewebekonzentrationen 
wurde gezeigt, dass die Leber das Hauptzielorgan für die orale CoQ10-Aufnahme 
darstellt, gefolgt von Niere, Herz und Gehirn. Im Vergleich zu Q10 führte die 
Aufnahme an Q10H2 zu einer signifikant höheren Akkumulation an Gesamt-CoQ10 in 
der Leber. In Übereinstimmung dazu konnte durch Q10H2-Supplementation auch ein 
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verstärkter Einfluss auf Genexpressionsebene in den untersuchten Geweben geltend 
gemacht werden. Aus genomweiten Expressionsanalysen in der Leber als 
Hauptzielorgan der 14 M SAMP1-Mäuse wurden 11 Q10H2-sensitive Gene 
identifiziert, die primär dem Cholesterolstoffwechsel, dem Lipidstoffwechsel, der 
Inflammation und der Zelldifferenzierung zuzuordnen waren. Unter Einbezug von 
Text-Mining-Analysen wurde für die identifizierten Q10H2-sensitiven Gene eine 
funktionelle Verbindung im PPARα-Signalweg postuliert. Diese Gene wurden nicht in 
den Lebergeweben der Q10-supplementierten Tiere reguliert. Außerdem zeigte 
CYP51 – ein Schlüsselgen der Cholesterolbiosynthese – eine gegenläufige 
Regulation in Lebergeweben von Q10H2- und Q10-supplementierten Tieren. Die 
Redox-Sensitivität der identifizierten Gene könnte eine mögliche Erklärung für die 
beobachteten unterschiedlichen Cholesterolkonzentrationen in der Leber von Q10H2- 
und Q10-gefütterten Tieren liefern.  
 
Zur weiteren Verifikation der in-vitro-Daten wurden 53 gesunde männliche 
Probanden über einen zweiwöchigen Zeitraum mit Q10H2 (150 mg/d) supplementiert. 
Mittels genomweiter Expressionsanalysen konnten 7 Q10H2-sensitive Gene in 
Monozyten identifiziert werden, die im Bereich Inflammation und Apoptose eine 
relevante Rolle spielen. Auf Grundlage von Text-Mining-Analysen wurden für die 
identifizierten Q10H2-sensitiven Gene funktionelle Verknüpfungen in PPAR- und 
NFκB-Signalwegen postuliert. Aufgrund der bekannten Funktion von PPARs im 
Lipidstoffwechsel und bei Zelldifferenzierungsprozessen wurden zusätzlich zu den 
transkriptionellen Veränderungen auch physiologische Parameter, wie LDL-
Cholesterolspiegel und  Blutzellenzahl miterfasst. Die Supplementation mit Q10H2 
führte zu einer signifikanten Abnahme der LDL-Cholesterolkonzentration im Serum. 
Darüber hinaus konnten signifikante Veränderungen im Differenzierungsgrad der 
roten Blutzellen (Erythrozyten- und Retikulozytenzahl) festgestellt werden.  
 
Zusammenfassend zeigen die Ergebnisse aus den in-silico-, in-vitro- und in-vivo- 
Studien, dass Q10H2 anti-inflammatorische Eigenschaften hat und an der Regulation 
des Cholesterolstoffwechsels und an Zelldifferenzierungsprozessen beteiligt ist. Die 
beobachteten Effekte sind zumindest teilweise durch einen Einfluss von Q10H2 auf 
die redox-sensitive und NFκB-/PPARα-abhängige Genexpression zu erklären.  
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AACS acetoacetyl-CoA synthetase 
BRE brain and reproductive organ-expressed 
CCL3 chemokine (C-C motif) ligand 3 
cDNA/RNA complementary DNA/RNA 
CFLAR caspase 8 and FADD-like apoptosis regulator gene 
CoQ10 coenzyme Q10 
CRP C-reactive protein 
CXCL2 chemokine (CXC motif) ligand 2 
CYP51 lanosterol 14α-demethylase 
FABP5 fatty acid binding protein 5 
GAPDH glyceraldehyde-3-phosphate dehydrogenase  
GIMAP7 GTPase, IMAP family member 7 
HDL high density lipoprotein 
HMGCL 3-hydroxy-3-methylglutaryl-coenzyme A lyase 
HMGCR 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
HMGCS1 3-hydroxy-3-methylglutaryl-coenzyme A synthase 1 
LPS lipopolysaccharide 
LXR liver X receptor 
MCH mean corpuscular haemoglobin 
MCHC mean corpuscular haemoglobin concentration 
MCP-1 monocyte chemoattractant protein-1 
MIP macrophage inflammatory protein 
MMD monocyte to macrophage differentiation factor 
MPA2L macrophage activation-2 like 
MPEG1 macrophage-expressed gene 1 
mRNA messenger RNA 
NFκB nuclear factor kappa B 
NMR nuclear magnetic resonance 
NR4A2 nuclear receptor subfamily 4, group A, member 2 
oxLDL oxidized LDL 
PLTP phospholipid transfer protein 
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 
PPAR peroxisome proliferator-activated receptor 
Q10 oxidized form of CoQ10 
Q10H2 reduced form of CoQ10 
qRT-PCR quantitative real-time PCR 
RANTES  regulated upon activation, normal T cell expressed and secreted 
RNA ribonucleic acid 
ROS reactive oxygen species 
RXR retinoid x receptor 
SAMP1 senescence-accelerated mice prone 1 
SREBF1 sterol regulatory element binding factor-1 
STAT1 signal transducer and activator of transcription 1 
TG triglycerides 
TNFα tumor necrosis factor alpha  
VLDL very low density lipoprotein 
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Structure and biosynthesis of Coenzyme Q10 
Coenzyme Q or ubiquinone (CoQ) contains a benzoquinone ring and a lipid side 
chain constructed with several isoprenoid units. The number of isoprenoid units is 
species-specific. In humans, CoQ10 is the dominant form of CoQ (Figure 1).  
 
 
 
 
 
 
Figure 1 Biochemical structure of CoQ10 
 
Coenzyme Q is synthesized in most mammalian cells. The endogenous synthesis of 
CoQ10 in humans occurs via the mevalonate pathway. This pathway includes a 
sequence of cellular reactions leading to the synthesis of farnesyl-pyrophosphate 
(Farnesyl-PP), a common substrate for the synthesis of cholesterol, dolichol, dolichyl-
phosphate, coenzyme Q10 (ubiquinone) and the prenylation of proteins [1]. In 
comparison to other isoprenoid lipids, CoQ10 contains a benzoate ring as a non-
isoprenoid moiety, which is originated from tyrosine. After condensation of the ring 
with the isoprenoid side chain, multiple enzymatic modifications and substitutions of 
the benzoate ring occur. Although the chronology of enzymatic steps is not totally 
disclosed yet, it is obvious that only one enzyme, the Farnesyl-PP synthase mediates 
the formation of dimethylallyl-PP and isopentenyl-PP in the mevalonate pathway [2].  
 
Uptake and distribution  
CoQ10 in the diet 
The average daily dietary intake of CoQ10 is between 3-5 mg [3]. Normal plasma 
CoQ10 levels are around 1 µg/ml [4-6]. For a significant increase of blood plasma 
concentrations to 2 µg/ml, CoQ10 intake amounts of at least 100 mg/day are required. 
As shown in table 1, even with a diet containing large amounts of CoQ10-rich foods, 
supplementation is necessary to increase CoQ10 concentrations in blood plasma 
about baseline levels.  
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Table 1 Coenzyme Q10 in the diet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are based on [3,7] 
 
Animal studies 
For determination of CoQ10-dependent effects, an uptake of exogenously 
administered CoQ10 by peripheral cells and tissues is an essential precondition. Early 
studies in rats and mice [8-12] at doses ranging from 10 to 123 mg/kg/day show 
increases of CoQ10 in liver and plasma only. One of the earliest reports studying the 
systemic distribution and uptake of [14C]-CoQ10 after intravenous application (0.6 
mg/kg) in guinea pigs indicated that uptake from blood to peripheral tissues occurred 
for as long as 24 h. Concentrations in the heart, adrenal gland and brain peaked at 
approximately 24 h [13]. The observed differences between these animal studies 
have been linked to CoQ9 concentration, which is the predominant endogenous form 
in rats and mice, whereas CoQ10 is in guinea pigs. However, studies utilizing higher 
doses of CoQ10 ranging from 150 to 650 mg/kg/day reported increased CoQ10 levels 
in tissues of rats and mice [14,15]. The increase of CoQ (CoQ9 and CoQ10) content 
was primarily affected by extension of supplementation period when compared to 
short-term applications of CoQ10 [15].  
 
 
Food CoQ10 content 
[µg/g] 
Daily Portion 
[g/day] 
CoQ10 Intake 
[mg/day] 
Chicken leg 17 120 2.0 
Beef heart 41 120 4.8 
Beef liver 19 120 2.3 
Lamb leg 2.9 120 3.5 
Herring 27 26 0.7 
Trout 11 100 1.1 
Orange 2.2 200 0.44 
Cauliflower 0.6 200 0.12 
Spinach 2.3 200 0.46 
Potato 0.24 200 0.05 
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Human studies 
In view of its biochemical structure, CoQ10 is nearly insoluble in aqueous solutions. 
Hence, after oral ingestion, exogenous CoQ10 is incorporated into chylomicrons for 
transport in the lymph to the peripheral blood [16]. Pharmacokinetics studies in 
humans indicate an increase of CoQ10 plasma levels about baseline – after fasting – 
after 1-2 h of oral administration [17-19]. Data from a recent study indicate a dose-
dependent increase in CoQ10 plasma concentrations after supplementation with 90 
mg, 150 mg or 300 mg of the reduced form of CoQ10 (Q10H2, ubiquinol) [17]. Most 
important, the increase of plasma levels per 100 mg values was remarkably higher 
when compared to the results obtained with the oxidized form (Q10, ubiquinone) [20]. 
However, with regard to the administration of Q10H2, only slight differences have 
been observed between 90 mg, 150 mg or 300 mg Q10H2 with respect to increase per 
100 mg (2.926, 2.457 and 2.550, respectively). Hence, the efficiency of absorption 
was not remarkable affected with increasing doses of Q10H2 in the described range. 
In general, in these studies plasma ubiquinol concentrations accounted for 96-98.5 % 
of total plasma CoQ10 [17]. This is comparable with natural occurring CoQ10 levels in 
healthy subjects [21-23]. However, in terms of increase over baseline values (fold 
change) and net increase per 100 mg, a more efficient absorption of CoQ10 in the 
reduced form (Q10H2) is assumed. 
  
Biological functions of CoQ10 
Coenzyme Q10 has been identified as a crucial cofactor in several biological 
processes including its electron carrier function in the respiratory chain, as proton 
carrier in membranes other than mitochondria and its cofactor function of uncoupling 
proteins (UCPs). Moreover, the reduced form of CoQ10 serves as a potent antioxidant 
in mitochondria and lipid membranes, as well as a regenerator of other lipid-soluble 
antioxidants. More recently, an impact of CoQ10 on gene expression has been 
identified. The main biological functions of CoQ10 are summarized in table 2. 
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Table 2 Overview of main biological functions of CoQ10 and their original 
publication dates  
Biological Function Publication 
Electron carrier in the respiratory chain Crane et al, 1957 
Proton carrier in other membranes than mitochondria Sastry et al., 1961 
Antioxidant of lipid membranes Sastry et al., 1961 
Cofactor of dihydroorotate dehydrogenase  Jones, 1980 
Regeneration of antioxidants Kagan et al., 1990 
Regulator of transition pore opening Fontaine et al., 1998 
Cofactor of uncoupling proteins (UCPs) Echtay et al., 2000 
Mediator of gene expression Groneberg et al., 2005 
 
Cofactor functions of CoQ10 
CoQ10 functions as a cofactor in the transport of electrons from mitochondrial 
respiratory chain complexes I and II to complex III [24,25]. Additionally, CoQ10 is 
required as a cofactor for the biosynthesis of pyrimidine nucleotides (dihydroorotate 
dehydrogenase) [26], as well as for the permeability transition pore opening [27] and 
uncoupling protein function (UCPs) [28].  
UCPs are located in the inner mitochondrial membrane and can translocate protons 
(H+) from the outside to the inside of mitochondria [28]. Five UCPs (1-5) are known in 
humans and CoQ10 has been identified as an obligatory cofactor for UCP function. 
The oxidized form (Q10) is able to mediate this essential function of CoQ10, however, 
the reduced form (Q10H2) is not [28].  
The inner membrane of mitochondria has a low permeability to ions so that the trans-
membraneous transport mechanisms are dependent on the presence of 
macromolecule transporters and ion channels. The permeabilization of the 
membrane is due to the opening of an inner mitochondrial complex, the permeability 
transition pore (PTP) [29]. CoQ10 has been shown to prevent PTP opening by 
counteracting mitochondrial membrane potential depolarization [30].  
Moreover, CoQ10 is involved in the biosynthesis of pyrimidine nucleotides. The 
de novo biosynthesis pathway contains six enzymes including dihydroorotate 
dehydrogenase (DHOD) [31,32]. CoQ10 has been identified as an essential 
compound in the biosynthesis of pyrimidine nucleotides as a cofactor for DHOD [26]. 
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Antioxidant action of CoQ10  
In general there are four major groups of naturally occurring lipid soluble antioxidants 
including carotenoids, tocopherols, estrogens and coenzyme Q. The redox functions 
of CoQ10 are due to its redox-dependent ability to exchange two electrons between 
the oxidized (ubiquinone) and reduced form (ubiquinol) (Figure 2). This redox-
dependent step can both be driven by simultaneous transfer of two electrons in a 
single step, or by two sequential steps of one electron transfer through a partially 
reduced semiquinone intermediate [33]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Schematic overview of the CoQ10 redox regulatory system 
 
A large amount of data collected by experiments on e.g. liposomes, mitochondria and 
lipoproteins of the blood demonstrated that CoQ10 acts in its reduced form (Q10H2, 
ubiquinol) as a potent antioxidant and inhibits lipid peroxidation [34]. The 
effectiveness of CoQ10 as an inhibitor of lipid peroxidation is based on its complex 
interaction during the peroxidation process. As shown in figure 3, its primary action is 
the prevention of lipid peroxyl radicals (LOO•) production during the initiation process. 
Thus, Q10H2 reduces the initiating perferryl radical with the formation of 
ubisemiquinone and H2O2. Additionally, Q10H2 might eliminate LOO• directly. It has 
also been demonstrated that Q10H2 regenerates the antioxidant vitamin E from α-
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tocopheroxyl radical [35]. Furthermore, CoQ10 has been shown to reduce protein 
oxidation [36], although not against all types of oxidative damage [37]. In general, the 
close spatial relationship of CoQ10 to the neighbouring membrane proteins seems to 
be a main factor for the observed protective effects of CoQ10 against lipid and protein 
oxidation, and moreover, DNA damage [38].   
 
 
Figure 3 Ubiquinol-mediated action on lipid peroxidation  
LH, polyunsaturated fatty acid; OH•, hydroxyl radical; Fe3+-O2• -, perferryl radical; 
CoQH2, reduced CoQ10; CoQH• -, ubisemiquinone; L•, carbon-centered radical; LOO•, 
lipid peroxyl radical; LOOH, lipid hydroperoxide; Vit-O•, α-tocopheroxyl radical; asc•, 
ascorbyl radical, (taken from Bentinger et al., 2007)   
 
Antioxidant role during aging 
It is widely recognized that during aging there is a pro-oxidizing shift in the cellular 
redox state [39]. This process is accompanied by oxidatively damaged molecules, 
which in turn play a causal role in senescence processes [40-43]. Generally, the 
CoQ10 content as well as the ratios of CoQ10 and CoQ9 vary in different organelles, 
tissues and species [44]. In mice, a 100-fold variation has been observed between 
different tissue homogenates [8,45] in the rank order kidney > heart > skeleton > 
muscle > brain > liver. However, it has to be taken into account that CoQ (CoQ9 and 
CoQ10) content of mitochondria was 6, 3, 4 and 23 times higher in liver, kidney, heart 
and skeletal muscle, respectively. Finally it seems that during aging CoQ 
concentrations primarily decrease in mitochondria [46-48] when compared to plasma 
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or tissue homogenates [47,49,50]. This assumption is also supported by further 
reports in mammalian species [51,52] demonstrating that the species-specific  
maximum life span is inversely correlated with mitochondrial rates of O2• ─ and H2O2 
generation. Moreover, the CoQ9 and CoQ10 content, as well as the ratio of these two 
are in turn correlated to O2• ─ generation [53]. For instance, CoQ9 content of cardiac 
mitochondria correlates directly and CoQ10 inversely with the rate of O2• ─ generation.  
 
Antioxidant role in the blood 
As indicated for most of the tissues, the majority of CoQ10 in blood plasma occurs in 
the reduced form, which is finally due to the activity of the membrane-bound 
NAD(P)H oxidoreductases [33,54-57] and FAD-containing homodimeric enzymes 
including e.g. lipoamide dehydrogenase or glutathione reductase [58]. In plasma, 
CoQ10 is mainly transported by low-density lipoprotein cholesterol (LDL) and other 
apolipoprotein B-containing proteins, as well as high-density lipoprotein (HDL) [59,60]. 
The basal content of CoQ10 in LDL, VLDL and HDL is approximately 1.0, 1.2 and 0.1 
nmol/mg protein, respectively. Following a single oral dose of 200 mg CoQ10, the 
mean amounts increased to 3.5, 3.2 and 0.3 nmol/mg protein [61]. Furthermore, in 
comparison to mean tissue antioxidant concentrations where CoQ10 is 6-10 times 
higher than vitamin E, its amount in the blood is only one-tenth of vitamin E. Due to 
the efficient reductase mechanisms, however, CoQ10 remains in its active form 
(Q10H2) and plays an important role in preventing oxidation of LDL particles and other 
lipid soluble antioxidants in the blood [62]. Since oxidized LDL is considered to play 
an important role in the development of atherosclerosis, the intervention with CoQ10 
is of great interest [63-65]. In contrast to red blood cells, which contain only minor 
levels of intracellular CoQ10, mononuclear (monocytes, lymphocytes) and polynuclear 
(granulocytes) white blood cells contain considerable amounts of CoQ10. 
Mononuclear cells were reported to have CoQ10 concentrations of 65 ± 24 pmol/mg 
protein [66]. Moreover, it has been shown that dietary administration in vivo 
increased CoQ10 content of monocytes and lymphocytes but not of polymorphic cells 
[67]. In general, not all observed effects on blood parameters can be explained by 
antioxidant mechanisms of CoQ10, as several oxidative stress markers have not been 
shown to decrease after supplementation [68]. Hence, it appears that other 
mechanisms than the antioxidant role of CoQ10 – probably mediated by gene 
expression [67,69] – might be relevant in blood cell metabolism.   
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Gene expression and CoQ10 
Previous and recent in vitro and in vivo studies indicate effects of Coenzyme on gene 
expression (Table 3). These effects might be mediated by interacting with a 
transcription factor. Alternatively, the autoxidation of the semiquinone radical formed 
in various membranes during electron transport activity is a primary basis for the 
generation of hydrogen peroxide (H2O2) [70]. H2O2 in turn can activate transcription 
factors such as nuclear factor kappa B (NFκB) [71,72]. In general there are distinct 
hints that reactive oxygen species (ROS) mediate modulatory effects on gene 
expression [71,73-77]. In addition to its well known function as an antioxidant [35,78], 
the impact of Coenzyme Q10 on gene expression needs to be further evaluated as 
indicated by the inadequate number of previous and recently published studies 
(Table 3). Especially studies reflecting effects of CoQ10 on gene expression in 
humans are lacking.  
 
Table 3 Overview about previous and recently published studies reflecting 
CoQ10 effects on gene expression 
Cell line/Species Cell/Tissue model References 
In vitro   
HeLa cells cervix Gorelick et al., 2004 
Caco-2 cells intestinum Groneberg et al., 2005 
LT97 and SW480 cells colon  Nohl et al., 2005 
THP-1 cells monocytes Schmelzer et al., 2009 
In vivo   
Humans skeletal muscle Linnane et al., 2002 
C57BL6 mice heart Lee et al., 2004 
C57BL6J mice liver Schmelzer et al., 2009 
C57BL6 mice liver Sohet et al., 2009 
SAMP1 mice liver, heart, brain, kidney Schmelzer et al., 2009, in 
press 
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Aim of the thesis 
The present thesis was focused on effects of Coenzyme Q10 on inflammatory 
processes and lipid metabolism by targeting gene expression. 
  
To support the hypothesis of a functional role of CoQ10 on gene expression, a text 
mining analysis was initially performed on data from a previous cell culture 
experiment in human Caco-2 cells [69].  
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microarray data from different tissues of SAMP1 mice were analyzed after 
supplementation of mice with the oxidized (Q10) or reduced form (Q10H2) of CoQ10 for 
6 or 14 months. 
 
Chapter III 
C. Schmelzer, H. Kubo, M. Mori, J. Sawashita, M. Kitano, K. Hosoe, I. Boomgaarden, 
F. Döring, K. Higuchi 
“Supplementation with the reduced form of Coenzyme Q10 decelerates 
phenotypic characteristics of senescence and induces a peroxisome 
proliferator-activated receptor-α gene expression signature in SAMP1 mice”. in 
press in Molecular Nutrition and Food Research  
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To determine putative anti-inflammatory and anti-apoptotic effects of Q10H2 in vivo, 
expression levels of genes and proteins related to inflammatory and apoptotic 
processes were examined in isolated monocytes and serum samples of Q10H2-
supplemented subjects.   
 
Chapter IV 
C. Schmelzer, P. Niklowitz, J. Okun, T. Menke, F. Döring 
“Effects of the reduced form of Coenzyme Q10 on gene expression, 
inflammation and cell differentiation in humans”. drafted manuscript 
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Coenzyme Q10 (CoQ10) is a lipid-soluble compound functioning as an essential 
cofactor in the respiratory chain [1,2] and serves as a potent antioxidant in 
mitochondria and lipid membranes [3,4]. Furthermore, CoQ10 acts as an obligatory  
cofactor for the dihydroorotate dehydrogenase [5] and for the function of uncoupling 
proteins (UCPs) [6]. More recently, CoQ10 has been identified in vitro as a modulator 
of genes involved in cell signalling, metabolism and transport [7]. In view of the 
antioxidant properties of the reduced form of CoQ10 (Q10H2), anti-inflammatory effects 
were hypothesized. In order to unravel putative effects of Q10H2 on inflammation and 
lipid metabolism on the transcriptional and physiological level, cell culture 
experiments in human monocytes as well as studies in SAMP1 mice and humans 
were performed in this thesis.  
 
To identify CoQ10-sensitive genes with putative functional connections in 
inflammatory processes, text-mining analysis was initially performed with gene 
expression data from a previous in vitro study [7] (Chapter I). For this purpose, 
intestinal Caco-2 cells were incubated with 50 µM CoQ10 for 24 h. Gene array 
technology revealed changes in steady-state levels of 464 genes at a threshold-
factor of at least 2.0 in three independent experiments. To decipher functional and 
regulatory connections between the identified CoQ10-inducible genes and more 
precisely, to define a putative role of CoQ10 in inflammatory processes, BiblioSphere 
PathwayEdition (BSPE) software package was used. To our knowledge, BSPE is the 
only currently available system combining literature analysis and promoter analysis. 
The primary source of BSPE is NCBI Pubmed, where about 15 million scientific 
abstracts are available for analysis of co-citations of uploaded gene names, 
synonyms and relation concepts. For transcription factor binding site analysis in 
promoter regions of co-citated genes, Genomatix MatInspector was additionally 
applied. From the combined literature and transcriptional factor binding site analysis 
with the concomitant inclusion of stringent criteria (GFG level B3), several CoQ10-
inducible genes were functionally connected with each other by signalling pathways 
of G-protein coupled receptors, JAK/STAT or integrin (Figure 1). Moreover, promoter 
analysis of genes which are related to inflammation revealed binding sites for the 
pivotal inflammatory transcription factor nuclear factor kappa B (NFκB) [8]. In 
summary, text mining analysis supported our hypothesis of CoQ10-modulating effects 
on the expression of inflammatory genes. A general impact of CoQ10 on gene 
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expression was also confirmed by other in vitro and in vivo studies [9-15]. However, 
with respect to these data, several side effects including e.g. autoxidation of the 
semiquinone intermediate (Q10H•) may also contribute to the observed effects of 
CoQ10 on gene expression. This is due to the fact that the Q10H•-mediated generation 
of hydrogen peroxides (H2O2) and reactive oxygen species (ROS) may also have a 
distinct impact on gene expression [16,17].    
 
 
Figure 1 Identification of putative connections and pathways of CoQ10-
sensitive genes by BiblioSphere PathwayEdition Software  
The indicated pathways have been identified by analysis of 464 CoQ10-inducible 
genes with the BiblioSpherePathwayEdition software package based on co-citations 
with transcription factors, functional co-citations, and co-citations with other genes in 
the network. The figure was modified according to Schmelzer et al. [18] and 
emphasizes genes with promoter binding sites for the transcription factor NFκB. 
BCAR1, Breast cancer anti-estrogen resistance 1; CRP, C-reactive protein; DHDDS, 
Dehydrodolichyl diphosphate synthase; F2, Thrombin; GNAQ, Guanine nucleotide 
binding protein; IAPP, Islet amyloide polypeptide; IL5, Interleukin 5; LTBP1, Latent 
transforming growth factor beta binding protein 1; ITGAV, vitronectin receptor; PTH, 
Parathyroid hormone; PYGM, Glycogen phosphorylase; RNASE2, Ribonuclease; 
SRC, V-src sarcoma; SST, Somatostatin; STAT6, Signal transducer and activator of 
transcription 6;  VTN, Vitronectin 
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With regard to the results from the in silico analysis (Chapter I), indicating modulatory 
effects of CoQ10 on inflammatory gene expression, the impact of pre-incubation with 
the reduced form of CoQ10 (Q10H2) on LPS-induced release of various key pro-
inflammatory mediators (TNFα, MIP-1α, RANTES and MCP-1) was studied in the 
monocytic cell line THP-1 (Chapter II). With respect to the literature data [19,20] and 
our own published results [21,22], most in vitro studies used oxidized CoQ10 (Q10). 
Although Q10 can be enzymatically converted into its reduced form [23], this step may 
be accompanied by the generation of reactive oxygen species (ROS) [24] with an 
additional impact on gene expression [16,17]. In general THP-1 cells were used as a 
model of human monocytes, because monocytic cells are relevant key players in a 
variety of inflammatory processes [25,26]. Triggering of cells with lipopolysaccharide 
(LPS), the major outer membrane component of gram-negative bacteria, induces 
downstream signalling cascades of the transcription factor NFκB [27]. This in turn 
leads to the translocation of NFκB from the cytoplasm to the nucleus, where it 
specifically binds to promoter regions of inflammatory genes [25,27]. Our working 
model suggests that, due to its antioxidant properties, Q10H2 may be able to reduce 
LPS-induced ROS generation with subsequent NFκB translocation into the nucleus 
and inflammatory gene expression (Figure 2). In this context, NFκB activity has been 
shown to be inhibited by various compounds with antioxidant properties [28,29].  
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Figure 2 A current working model illustrating the anti-inflammatory role of 
Q10H2 by targeting gene expression  
 
The in vitro results in the monocytic cell line THP-1 suggest distinct reducing effects 
of Q10H2 on the release of key pro-inflammatory cytokines (TNFα) and chemokines 
(RANTES, MIP-1α) (Chapter II). In contrast, no effects were observed for MCP-1. 
These effects were comparable to a previous study in THP-1 cells, where the 
oxidized form of CoQ10 (Q10) was used [21]. However, with regard to this study, anti-
inflammatory effects on the LPS-induced release of inflammatory mediators were 
slightly more pronounced with Q10H2 when compared to Q10. Although it has been 
shown that Q10 can be efficiently converted into its reduced form by various enzymes 
[30-33], the localization of Q10 reductases differs considerably between cell types and 
compartiments. Thus, a compartmentalization of reductase activities in the cell, and 
moreover, the clarification of mechanisms underlying the incorporation of CoQ10 in 
the plasma membrane may give a further hint for the efficiency of Q10 reduction. With 
regard to the current knowledge on membrane dependent reductase mechanisms, a 
direct incubation with Q10H2 seems to be most effective. In this respect, dose-
dependent intracellular increases of total CoQ10 as well as relative levels of Q10H2 
have been observed after Q10H2 incubation (0.1 – 100 µM) in THP-1 cells [34].  
In view of the in vitro experiments indicating stronger anti-inflammatory effects of 
Q10H2 when compared to Q10 [21,35], redox-dependent gene expression patterns 
were hypothesized. To determine this assumption under physiological conditions, a 
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genome-wide expression profiling in various tissues (liver, kidney, heart and brain) of 
SAMP1 mice supplemented with Q10H2 or Q10 (500 mg/kg BW/d) for 6 or 14 months, 
respectively, was performed (Chapter III). SAMP1 mice were used because besides 
other manifestations of the aging process, they also show a higher oxidative stress 
status [36,37]. Hence, they are a suitable model to study putative effects of 
antioxidants on physiological and molecular readouts. Based on gene expression 
data, liver has been shown to be the main target tissue of CoQ10 intervention, 
followed by kidney, heart and brain. A prior accumulation of oral and/or intra-
peritoneal administered CoQ10 in the liver of rodents has been already described 
before [38-41]. One possible reason for this effect could be the primary incorporation 
of CoQ10 in LDL particles for its transport in the blood and subsequent accumulation 
in liver tissues [42]. CoQ10-mediated preventions of LDL oxidation processes have 
been already described in vitro and in vivo [43-46]. Moreover, stringent evaluation of 
array data revealed a stronger impact on gene expression by Q10H2 when compared 
to Q10. This might be due to differences in the bioavailability. In fact, Q10H2 
supplementation was more effective than Q10 to increase CoQ10 levels in the liver of 
SAMP1 mice. This was also indicated by plasma levels of a previous study in SAMP1 
mice [47] and humans [48,49]. To explore long-term effects of Q10H2-
supplementation on the transcriptional level, a more detailed analysis of the array 
data was performed in liver tissues of SAMP1 mice supplemented with Q10H2 for 14 
months. Finally, 11 Q10H2-sensitive genes have been identified, primarily related to 
cholesterol (HMGCS1, HMGCL, HMGCR) and lipid/lipoprotein metabolism (AACS, 
SREBF1, FABP5, PLTP) as well as inflammation (STAT1) and cell differentiation 
processes (MMD2, MPEG1, MPA2L). Results from text mining revealed an 
involvement of these genes in PPARα signalling pathways. Interestingly, these genes, 
with the exception of SREBF1, were only regulated in liver tissues of Q10H2-
supplemented animals when compared to Q10-treated mice. This was also shown by 
the subsequent results from qRT-PCR verification experiments for these genes and 
additional genes playing also a key role in the cholesterol biosynthesis pathway 
(unpublished results). Moreover, CYP51, was significantly down-regulated in the 
Q10H2-treated group, but became up-regulated in Q10-supplemented animals. The 
encoded protein of this gene plays a key role in the demethylation process of 
lanosterol, a relevant metabolite in the cholesterol biosynthetic pathway. These data 
show, to our knowledge for the first time, redox-dependent gene regulatory effects of 
General Discussion 
 21 
CoQ10 in vivo. Furthermore, our data from liver tissues of SAMP1 mice also show 
pronounced differences in cholesterol content of Q10H2 and Q10-supplemented mice 
with distinct higher levels in the Q10H2-group (unpublished results). As the key 
regulator genes of cholesterol biosynthesis were simultaneously down-regulated in 
the Q10H2-treated group, a negative feedback mechanism of liver cholesterol 
concentration on the transcription of cholesterol biosynthetic genes is suggested. A 
negative feedback loop in liver cholesterol metabolism has been already described 
previously [50-53] and was reported to be mediated by lanosterol 14alpha-
demethylase (CYP51) through binding of sterol regulatory element binding proteins 
(SREBPs) [54-57]. It would be interesting to know under future studies whether 
effects on various up- and downstream metabolites of lanosterol demethylase 
(CYP51) including e.g. lanosterol, lathosterol, 7-dehydro-cholesterol and desmosterol 
(Figure 3) are also existent. Potential differences in the bioavailability of Q10H2 and 
Q10 with an additional impact on cholesterol absorption could also be determined by 
major plant sterol concentrations of e.g. beta sitosterol, stigmastanol and 
campesterol in the respective liver samples. This is due to the fact that plant sterols 
are chemical homologues of cholesterol, which have been shown to interfere with 
cholesterol in the intestine, and thus reduce the efficiency of its absorption [58].  
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Figure 3 Scheme of the cholesterol biosynthetic pathway including the 
intermediates assumed to be differently affected by Q10H2 or Q10 
treatment through lanosterol demethylase (CYP51) expression  
Dotted arrows depict intermediates of the cholesterol biosynthetic pathway that 
accumulate in a tissue-specific manner and have other physiological roles than 
related to cholesterol metabolism. Cholesterol metabolites are indicated by dashed 
arrows. The lanosterol demethylase is boxed. Encircled terms reflect intermediates 
with a putative different accumulation in liver tissues of Q10H2 and Q10-supplemented 
SAMP1 mice. (modified after Debeljak et al., 2003) 
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As described in chapter III, the observed regulatory effects of Q10H2 on genes 
involved in cholesterol and lipid metabolism, cell differentiation/proliferation 
processes and inflammation are hypothesized to be mediated through PPARα 
signalling. PPARα-mediated effects on lipid metabolism as well as inflammatory and 
differentiation processes have been already described previously [59-64]. Finally, 
three putative functions of Q10H2 were proposed for PPARα-mediated signalling 
processes (Chapter III): 1. as an antioxidant, leading to decreased levels of LXR 
agonists 2. as an antagonist of LXR, leading to PPARα/RXR heterodimers and 
PPRE activation and 3. as an agonist of PPARα, leading to PPARα/RXR 
heterodimers and PPRE activation. As the identified gene pattern was not found in 
liver samples of Q10-supplemented mice, a Q10H2-specific effect due to its antioxidant 
properties and/or bioavailability was suggested. In this context, dietary effects on 
PPARα signalling pathways have already been described in mice for other lipophilic 
antioxidants such as α-tocopherol [65]. Although the exact mechanism of Q10H2-
PPARα interaction cascades has not been definitely clarified, our results support a 
regulatory role of Q10H2 in PPARα signalling processes. 
 
As the data from the in vitro experiments indicated slightly stronger anti-inflammatory 
effects of Q10H2 when compared to Q10 [21,35], a 2-week human intervention study 
was performed with Q10H2 (150 mg/d) in 53 healthy male volunteers (Chapter IV). 
Monocytes were isolated from volunteers before (T0) and after (T14) supplementation 
with Q10H2 to obtain expression changes of genes related to inflammatory and 
apoptotic processes. In this context anti-inflammatory [21,22,35] and anti-apoptotic 
[66-70] effects of CoQ10 have been already described in vitro. However, most 
published studies examined effects of the oxidized form of CoQ10 [19,20,71,72]. To 
our knowledge, this is the first study investigating anti-inflammatory and anti-
apoptotic effects of the reduced form of CoQ10 (Q10H2) in a healthy study population. 
As all determined effects in this study were related to a simple one-group pre-post 
analysis, additional criteria were implemented to evaluate the compliance of Q10H2 
supplementation and its subsequent effects on gene expression in isolated 
monocytes of study subjects. Thus, the involvement of additional monocyte and 
plasma samples from volunteers after a 4-week washout period was considered as 
an alternative approach for the reliability of data from non-placebo controlled 
intervention studies and has been already described in the literature [73]. Moreover, 
General Discussion 
 24 
the reliability of the microarray data was additionally confirmed by using quantitative 
real-time PCR (qRT-PCR) for selected target genes. In view of the consistent data 
obtained from microarray as well as technical and biological verification experiments, 
7 Q10H2-sensitive genes (TNFα, CXCL2, CCL3, GIMAP7, NR4A2, BRE and PMAIP1) 
related to inflammatory and apoptotic responses were identified in isolated 
monocytes of the study subjects. To verify these effects also on the protein level, 
relevant key inflammatory mediators in monocytes (TNFα, CXCL2, MCP-1, CRP) 
were additionally determined in serum samples of study subjects. However, neither in 
native nor in ex vivo LPS-stimulated whole blood samples significant changes were 
found for the selected parameters. The observed discrepancies between the in vitro 
results (Chapter II) and the present data may be due to the heterogeneous cell 
populations in whole blood from which serum or plasma samples were separated for 
subsequent experiments. In fact, differences in gene expression were already 
indicated by studies in different leukocyte subpopulations, where more stable 
expression profiles were achieved by positive selection of certain cell types [74]. 
Furthermore, post-transcriptional mechanisms including mRNA degradation or 
transrepression by complementary micro RNAs [75] as well as posttranslational 
mechanisms [76] may also account for the unaltered effects on protein levels. Based 
on gene expression results, text mining application (BibliosSphere Pathway Edition) 
revealed an involvement of these genes in NFκB and PPAR-signalling pathways. As 
our previous study in liver tissues of Q10H2-supplemented SAMP1 mice revealed 
PPARα gene expression patterns related to lipid metabolism and cell 
differentiation/proliferation processes (Chapter III), the present study was additionally 
focused on the alteration of respective physiological parameters. Finally, significant 
reductions of LDL cholesterol levels have been obtained in serum samples of Q10H2-
supplemented subjects with two independent methods (routine laboratory detection 
vs. NMR-based technology). Although the absolute amount of LDL cholesterol 
differed with regard to the applied method of measurement, the observed effects 
were in qualitative agreement. With regard to array data from SAMP1 mice [15] and 
human study experiments, common regulated genes related to cell differentiation 
processes (e.g. MMD2) have been identified. Accordingly, significant effects on 
haematological parameters including e.g. the number of erythrocytes and 
reticulocytes have been additionally observed in the human study. These 
physiological alterations are a first hint for directly mediated effects of Q10H2 on cell 
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differentiation/proliferation processes in vivo, or more explicitly, on the process of 
erythropoiesis [77]. However, the observed effects might also be ascribed to the 
radical scavenging activity of Q10H2 [78,79], finally leading to a decreased ROS 
concentration. This is due to the fact that ROS may also function as signalling 
intermediates, finally contributing to cellular functions such as proliferation and 
differentiation [80]. In this context, the antioxidant scavenger enzyme peroxiredoxin 1 
(PRDX1) has been described as a key regulator of neuronal cell proliferation 
processes in vitro. Although the suggested mechanisms in monocytic cells could only 
in part explain the observed effects on haematological parameters, a modulatory role 
for Q10H2 in the process of erythropoiesis was suggested.  
In summary, it is hypothesized that the reduced form of CoQ10 (Q10H2) induces the 
NFκB- and/or PPARα-mediated signalling cascade through its antioxidant properties. 
This may in turn also explain the observed anti-inflammatory and anti-apoptotic 
effects on gene expression.  
 
In conclusion, the results from the in silico, in vitro and in vivo studies show anti-
inflammatory properties of Q10H2 as well as a regulatory role in cholesterol 
metabolism and cell differentiation processes. These effects might be explained, at 
least in part, by a modulatory impact of Q10H2 on redox-sensitive NFκB/PPARα 
dependent gene expression.  
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Functional Connections and Pathways of Coenzyme Q10-inducible
Genes: An In-silico Study
Constance Schmelzer1, Inka Lindner1, Christina Vock1, Kenji Fujii2 and Frank Do¨ring1
1Institute of Human Nutrition and Food Science, Molecular Nutrition, Christian-Albrechts-University of Kiel, Germany
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Summary
Coenzyme Q10 (CoQ10, ubiquinone) is an essential cofactor in
the electron transport chain, serves as a potent antioxidant in
mitochondria and lipid membranes, and is often used as a dietary
supplement for a number of diseases including cardiovascular
diseases. Recently, we obtained evidence that CoQ10 (Kaneka
Q10
TM) affects the expression of hundreds of human genes. To
decipher the functional and regulatory connections of these genes, a
literature search combined with transcription factor binding site
analysis was performed using Genomatix BiblioSphere and
MatInspector. This in-silico analysis revealed 17 CoQ10-inducible
genes which are functionally connected by signalling pathways of G-
protein coupled receptors, JAK/STAT, integrin, and beta-arrestin.
Promoter analysis of these CoQ10-inducible genes showed one group
of NFkB-regulated genes, namely IL5, thrombin, vitronectin
receptor and C-reactive protein (CRP). Furthermore, a common
promoter framework containing binding sites of the transcription
factor families EVI1, HOXF, HOXC, and CLOX was identified in
the promoters of IL5, CRP, and vitronectin receptor. The identified
CoQ10-inducible genes and pathways play an important role in
inflammatory response. Since these effects are based on an in-vitro
study, the effect of CoQ10 on vascular health in vivo needs to be
addressed in further animal and/or human intervention studies.
IUBMB Life, 59: 1–6, 2007
Keywords Coenzyme Q10; in-silico analysis; cardiovascular diseases.
INTRODUCTION
Coenzyme Q10 (CoQ10) is an essential electron carrier and
proton translocator in the mitochondrial respiratory chain (1).
CoQ10 is also an obligatory cofactor of the dihydroorotate
dehydrogenase (2) and serves as a potent antioxidant in
membranes by directly scavenging radicals (3, 4) and
regenerating a-tocopherol (5 – 7). More recently, the role of
CoQ10 in the function of uncoupling proteins was discussed
(8 – 10). The functional diversity of CoQ10 reﬂects its
suitability for applications in clinical studies as an dietary
supplement for a number of diseases (11). These include
Parkinson’s disease (1, 12 – 15), mitochondrial myopathies (16,
17), age-related macular degeneration (18), migraine (19),
idiopathic asthenozoospermia (20, 21), and cardiovascular
diseases (22 – 24). The molecular mechanisms by which CoQ10
mediates these beneﬁcial eﬀects are uncertain. We (25) and
others (26, 27) obtained evidence that CoQ10 inﬂuences the
expression of hundreds of genes involved in diﬀerent cellular
pathways. To decipher the functional and regulatory connec-
tions of these genes we employed bioinformatic techniques to
access the actions of CoQ10 in detail. This in-silico approach
revealed that CoQ10 modulates inﬂammatory pathways via
gene expression. Thus, some of the eﬀects of CoQ10 on
vascular health may be due to this property.
MATERIAL AND METHODS
In-Silico Analyses
We used the freely-available part of Genomatix Software
2006 (www.genomatix.de). The CoQ10-regulated genes were
taken from our recent publication (25). In that study, we
incubated intestinal Caco-2 cells with 50 mM CoQ10 of a
liposomal preparation for 24 h. After exposition, gene array
technology revealed changes in steady-state mRNA levels for
hundred of human genes. The accession numbers of these
CoQ10-regulated genes (25) were uploaded to BiblioSphere-
PathwayEdition (BSPE). This text mining tool identiﬁes
functional connections based on co-citations of gene names
and synonyms (28). The co-citation ﬁlter ‘gene . . . function
word . . . gene’ (GFG level B3) was applied. The
accession numbers of ﬁltered genes were then uploaded to
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Gene2Promoter software which allowed the identiﬁcation of
promoter regions based on individual transcripts (29). The
obtained promoter sequences were adjusted to 600 bp, 500 bp
upstream and 100 bp downstream of transcriptional start
sites, and deposited inMatInspector to identify functional and
common modules in input promoters (30, 31). A common sites
analysis was performed. We chose only models common to at
least three input sequences (60%). The minimum and
maximum distance between two elements was chosen 5 and
50 bp, respectively.
RESULTS
The Text-mining System BiblioSpherePathwayEdition
(BSPE) Revealed 17 CoQ10-senstive Genes which
are Functionally Connected by Four Different
Pathways
Recently, we identiﬁed 464 diﬀerentially regulated genes in
the intestinal Caco-2 cell line after CoQ10-treatment at a
threshold-factor of at least 2.0 in three independent experi-
ments (25). These genes were used to identify their putative
functional connections by using the text-mining system
BSPE. Of 464 uploaded transcripts, 413 were recognized by
the program. Transcripts which showed co-citations with
transcription factors, functional co-citations (GFG level B3)
and co-citations with other genes of the input list were
selected. Based on these stringent criteria, we identiﬁed 19
CoQ10-inducible genes whereby 17 genes are functionally
connected by signalling pathways of G-protein coupled
receptors, JAK/STAT, integrin, and beta-arrestin (Fig. 1,
Table 1). Since ﬁve of these genes code for proteins involved
in inﬂammation (IL5, thrombin, vitronectin, vitronectin
receptor, C-reactive protein), a sub-analysis was performed.
As shown in Fig. 2, these genes are connected by the
transcription factor NFkB1.
The MatInspector-based Promoter Analysis of 17
Connected CoQ10-senstive Genes Revealed
Common Regulatory Modules in Three
Inflammatory Genes
To identify putative functional and common frameworks in
the regulatory regions of the 17 identiﬁed CoQ10-inducible
genes, their promoter sequences were extracted from NCBI
GenBank using Genomatix Gene2Promoter software and
were deposited in MatInspector. We searched for common
frameworks containing at least two transcription factor
binding sites (TFBS) at a distance between 5 and 50 bp, and
the quorum constraint was adjusted to 60%. The search
was done with combinations of ﬁve promoter sequences.
A framework common to all input promoters or common
frameworks with ﬁve elements was not found. Whereas
frameworks with two or three elements are common in input
genes, we identiﬁed only one framework with four elements.
As shown in Fig. 3, a common framework containing the
binding sites of the transcription factor families EVI1
(ecotropic viral integration site 1 encoded factor), HOX
(homeodomain transcription factor) and CLOX (cut-like
homeo box) were found in the promoters of IL5, C-reactive
protein, and vitronectin receptor.
DISCUSSION
In this study we have performed an in-silico approach to
decipher the functional and regulatory connections of 464
human genes which were recently identiﬁed (25) as ‘CoQ10-
inducible’. To obtain convincing connections we combined a
literature analysis with a transcriptional factor binding site
search. A recent analysis of genes encoding small leucine rich
proteoglycans showed indeed, that this combined analysis
seems to be more predictive than sole searches for transcrip-
tion factor binding sites (32, 33). Although the analysed
CoQ10-inducible gene can be grouped according to for
example mitochondrial respiration or plasma membrane
redox component, our strategy with rigorous criteria revealed
that 17 CoQ10 inducible genes are connected by four diﬀerent
cellular signalling pathways. Whereby, the genes of IL5,
thrombin, vitronectin, vitronectin receptor, and C-reactive
protein (CRP) seem to be regulated by NFkB1 and promoter
frameworks containing the transcription factors EVI, HOX,
and CLOX. Although the precise roles of these transcrip-
tional factors are not completely unravelled, they are
essentially involved in diﬀerent aspects of development and
are linked to several human diseases including inﬂammation
(34 – 37). Accordingly, IL5, thrombin, vitronectin and its
receptor as well as CRP are key components in similar steps
of inﬂammation processes. Although the in-vivo relevance of
these eﬀects has to be clariﬁed, an up-regulation of these
genes could for example sensitize the inﬂammatory responses
of monocytes.
Whereas IL5 is mainly responsible for the tissue damage
observed in allergic disorders (38), the other identiﬁed genes
seem to be important in the development of atherosclerosis.
CRP has been reported as a potent peptide that causes
platelet adhesion to epithelial cells, thereby regulating
atherothrombosis (39). This step is also regulated by
vitronectin and its receptor, since they interact with thrombin
and antithrombin III (40). The ﬁnding that expression of
vitronectin and its receptor is modulated by CoQ10 is
particularly interesting for several reasons. First, plasma
vitronectin levels are increased in patients with coronary
atherosclerosis (41). Second, it has been shown that
vitronectin-mediated cell survival also includes regulation
of NFkB-activity (42). Third, vitronectin is essential for
monocyte adhesion to endothelium (43). Finally, dose-, and
time-dependent inhibitory properties of CoQ10 on platelet
aggregability have been already shown in a previous study
with swine (44). Another study indicated a signiﬁcant
inhibition of vitronectin-receptor expression in human
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Figure 1. BiblioSphere Pathway view network of input genes regulated by CoQ10. A network of 17 genes was identiﬁed by
analysis of 464 CoQ10-inducible genes with the BiblioSpherePathwayEdition software package based on co-citations with
transcription factors, functional co-citations, and co-citations with other genes in the network. The abbreviations and
descriptions are listed in Table 1. The genes DNTT and NP are not part of the network. IN, input gene; ST, gene product is part
of a Genomatix signal transduction pathway; STKE, gene is part of a SignalTransductionKnowledgeEnviromental connection
map.
Mo
no f
or p
rint
colo
ur o
nlin
e
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platelets throughout CoQ10 treatment (45). Therefore, one
possible mechanism by which CoQ10 produces positive eﬀects
in cardiovascular diseases is through platelet inhibition. This
putative beneﬁcial mechanism is accompanied by other
eﬀects of CoQ10 on cardiovascular diseases. This includes
protection of LDL from oxidation, prevention of free-radical
damage caused by neutrophils and reduction of oxidative
injury by endothelial cells (11, 46, 47). Of course, based on
our in-vitro data the eﬀect of CoQ10 on vascular health in
vivo need to be studied in future animal and/or human
intervention studies. In those studies, tissue speciﬁc eﬀects
have to be taken into account. Further, the applied CoQ10
concentration of 50 mM for 24 h in vitro is diﬃcult to achieve
in humans. On the other side, the exposure time in vivo is
quite longer than in our in-vitro study. Again, in-vivo studies
are necessary to evaluate the eﬀect of CoQ10 on gene
expression and vascular health. In addition, future analysis of
the gene expression data on protein and metabolite level is
necessary.
Taken together, based on our in-silico analysis of more than
400 CoQ10-inducible genes, we obtained evidence that a part
of the CoQ10 regulation plays an important role in inﬂamma-
tory response. Since these eﬀects are based on in-vitro study,
the eﬀect of CoQ10 on vascular health in-vivo needs to be
addressed in further animal and/or human intervention studies.
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Table 1
CoQ10-inducible genes in the identiﬁed network (see Fig. 1)
Symbol Transcripta Description
Fold change
by CoQ10
b
SST NM_001048 Somatostatin þ2.3
IL5 NM_000879 Interleukin 5, colony-stimulating factor, eosinophil þ5.6
F2 NM_000506 Coagulation factor II, thrombin þ2.4
RNASE2 NM_002934 Ribonuclease, RNase A family þ16.0
PYGM NM_005609 Glycogen phosphorylase þ3.5
ITGAV NM_002210 Integrin alpha V, vitronectin receptor þ3.0
DNTT NM_004088 Deoxynucleotidyltransferase, terminal þ3.3
STAT6 NM_003153 Signal transducer and activator of transcription 6, interleukin-4 induced þ2.6
LTBP1 NM_000627 Latent transforming growth factor beta binding protein 1 þ2.7
CRP NM_000567 C-reactive protein, pentraxin-related þ3.0
GNAQ NM_002072 Guanine nucleotide binding protein, G protein, q polypeptide þ3.1
PTH NM_000315 Parathyroid hormone þ2.8
IAPP NM_000415 Islet amyloid polypeptide þ4.9
BCAR1 NM_014567 Breast cancer anti-estrogen resistance 1 þ2.9
PLCB1 NM_015192 Phospholipase C, beta 1 þ4.6
DHDDS NM_024887 Dehydrodolichyl diphosphate synthase þ2.6
VTN NM_000638 Vitronectin þ4.1
SRC NM_005417 V-src sarcoma þ2.8
NP NM_000270 Nucleoside phosphorylase þ3.9
aNCBI GenBank Accession number.
bObserved by array analysis as described (25): expression data were normalized to average expression levels of three housekeeping genes, namely, ß-actin,
GAPDH and ubiquitin.
Figure 2. BiblioSphere Pathway view network of input genes
which are involved in inﬂammation and regulated by CoQ10.
The network of ﬁve selected genes was obtained with
BiblioSpherePathwayEdition software package based on co-
citations with transcription factors, functional co-citations,
and co-citations with other genes in the network. The
abbreviations and descriptions of genes were listed in Table 1.
IN, input gene; ST, gene product is part of a Genomatix signal
transduction pathway; TF, transcription factor.
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Copyright © 2009 JCBNSummary Ubiquinol-10 (QH2), the reduced form of Coenzyme Q10 (CoQ10) serves as a potent
antioxidant of lipid membranes. Because many antioxidants reveal potent anti-inflammatory
effects, the influence of QH2 on lipopolysaccharide (LPS)-induced pro-inflammatory cytokines
and chemokines were determined in the human monocytic cell line THP-1. Stimulation of cells
with LPS resulted in a distinct release of Tumour necrosis factor-alpha (TNF-α), Macrophage
inflammatory protein-1 alpha (MIP-1α), Regulated upon activation, normal T cell expressed
and secreted (RANTES) and Monocyte chemotattractant protein-1 (MCP-1). The LPS-induced
responses were significantly decreased by pre-incubation of cells with QH2 to 60.27 ± 9.3%
(p = 0.0009), 48.13 ± 6.93% (p = 0.0007) and 74.36 ± 7.25% (p = 0.008) for TNF-α, MIP-1α and
RANTES, respectively. In conclusion, our results indicate anti-inflammatory effects of the
reduced form of CoQ10 on various proinflammatory cytokines and chemokines in vitro.
Key Words: coenzyme Q10, ubiquinol-10, inflammation, monocytes
Introduction
Exposure of cells to the pro-inflammatory lipopoly-
saccharide (LPS) triggers TLR4-dependent phosphorylation
cascades which lead to activation of NFκB. This central
transcription factor induces the expression and subsequent
secretion of various pro-inflammatory cytokines and
chemokines [1–3]. Reactive oxygen species (ROS) are
important for the activity of the TLR4-signalling pathway
[4]. Accordingly, antioxidants are described as anti-
inflammatory agents [5, 6]. Because Coenzyme Q10 (CoQ10)
is a potent antioxidant, we postulated that this molecule
possesses anti-inflammatory properties. More recently was
shown that CoQ10 supplementation minimizes oxidative
stress during statin drug therapy [7]. Indeed, we found a
reduction of LPS-induced cytokine release by CoQ10 in
murine and human monocytic cell lines [8]. In the latter
study, we treated cells with the oxidized form of CoQ10
(ubiquinone-10) which is converted intracellular to
ubiquinol-10 (QH2). As only the reduced form of CoQ10 can
act as an antioxidant, here we studied effects on secretion of
the cytokine TNF-α and different chemokines in LPS-
stimulated THP-1 cells that were directly incubated with QH2.
Material and Methods
Reagents
Lipopolysaccharide (LPS, E.coli O55:B5) was obtained
from Sigma-Aldrich (Taufkirchen, Germany). The aqueous
solutions of ubiquinol-10 (PEG-60 hydrogenated castor oil,
ubiquinol-10, glycerol, water) and the corresponding
vehicle (no ubiquinol-10 supplement) were received from
KANEKA Corporation (Osaka, Japan).
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Cell culture
Cultivation of THP-1 cells occurred routinely in RPMI
medium 1640 supplemented with 10% FCS and 1% anti-
biotics (penicillin/streptomycin) in a humidified incubator
containing 5% CO2 at 37°C. For determination of TNF-α
and chemokines, cells were plated at a density of 0.5 × 106
cells in a 12-well plate for 24 h before pre-incubation.
Subsequently, cells were preincubated with either 10 µM
ubiquinol-10 or the reference substances pyrrolidine-
dithiocarbamate (PDTC) or N-acetyl-cysteine (NAC), or the
respective vehicle control. After 24 h, cell culture medium
was removed and fresh LPS-containing medium (1 µg/ ml)
was added for 4 h. Finally, for cytokine determination via
ELISA, supernatants were kept and stored at −80°C. For
protein determination via the BRADFORD method, cells
were collected into NET-buffer.
Cytotoxicity
For determination of cell viability, the Cell-Titer Glo®
Luminescent Assay was used. Thus, total ATP levels were
measured as an index of the viable cell number. The
luminescence was detected on a GloMax® (Promega,
Mannheim, Germany).
Determination of TNF-α and chemokines
Using TNF-α as an internal control, this cytokine was
determined by DuoSet ELISA (R&D Systems, Wiesbaden,
Germany) as well as multiplex suspension array technology
(BioRad, Munich, Germany) according to the manufacturer’s
instructions. The chemokines MCP-1, MIP-1α and RANTES
were determined by the multiplex suspension array system.
Protein concentration
Cells were collected into NET-buffer (50 mM TRIS
[pH 7.5], 150 mM NaCl, 1 mM EDTA [pH 8.0], 0.5%
NP-40) and the cell suspension was treated with ultrasonics
and then centrifugated by 14000 rpm at 4°C for 20 min.
Determination of protein concentration occurred in the
resulting supernatant by the Bradford method according to
the manufacturer’s instructions.
Statistics
All data are results of two (PDTC, NAC) or three (QH2)
independent biological experiments performed in duplicate
and expressed as means ± standard error of the mean (SEM).
Results were analyzed by an unpaired two-sided Student’s
t-test using SPSS 11.5 for Windows and GraphPad Prism 4.0
software. p-values less than or equal to 0.05 were considered
statistically significant.
Results and Discussion
NFκB is a multisubunit transcription factor that is ubiqui-
tously expressed in different cell types and can be activated
by several agents such as LPS, TNF-α or the oxidant
hydrogen peroxide (H2O2) [9]. This activation process
includes phosphorylation of the IκB subunit and its
dissociation from the inactive cytoplasmic complex. Thus,
the active dimer of p50 and p65 translocates into the nucleus
where specific target genes of pro-inflammatory mediators
and cytokines become immediately up-regulated [9, 10].
However, this NFκB-activating cascade was shown to be
inhibited by antioxidants such as PDTC and NAC. This
has led to the hypothesis that oxygen radicals are key players
in the activation of NFκB through an redox-dependent
mechanism [9, 11, 12]. Because many antioxidants reveal
potent anti-inflammatory effects, the influence of QH2 on
LPS-induced pro-inflammatory cytokines and chemokines
was determined in the human monocytic cell line THP-1. All
experiments were performed with the well known radical
scavengers PDTC and NAC to validate the putative anti-
inflammatory effects of QH2. To implement culture condi-
tions that do not lead to unspecific side effects, cell vitality
was measured at different medium concentrations of QH2.
As shown in Table 1, no cytotoxic effects were found for
PDTC (100 µM), NAC (100 µM) and QH2 (1, 10, 100 µM).
For further experiments we used 10 µM QH2, because this
concentration leads to a significantly higher intracellular
QH2 content in THP-1 cells and is also achievable in human
serum through QH2 supplementation (unpublished results).
As shown in Figure 1A-D, unstimulated THP-1 monocytes
secrete low amounts of the pro-inflammatory cytokine TNF-
α and chemokines MIP-1α, RANTES and MCP-1 into the
medium. However, stimulation with LPS induces approxi-
mately 58-(TNF-α), 7-(MIP-1α), 2-(RANTES) and 4-
(MCP-1) fold higher levels of these pro-inflammatory
Table 1. Effect of ubiquinol-10 (QH2) and the reference substances PDTC and NAC on viability of THP-1 cells.
THP-1 cells were either treated with 1–100 µM QH2 or 100 µM PDTC or NAC for 24 h. Medium was used as negative control (data not
shown) and 10% dimethyl sulfoxide (DMSO) as positive control (poco, positive control). The applied amount of the vehicle (veco) was in
accordance to 100 µM QH2. The cell viability of the negative control was set to 100% and the other values (means ± SEM) were
referenced to it. Three independent experiments were performed in triplicate.
10% DMSO Vehicle control 100 µM PDTC 100 µM NAC 1 µM QH2 10 µM QH2 100 µM QH2
% 1.71 148.87 109.44 92.51 120.74 109.68 98.43
±SEM ±0.36 ±15.09 ±22.33 ±21.38 ±13.20 ±15.70 ±16.09
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agents in the cell culture medium within 4 h, respectively.
Next, we tested the effect of pre-incubation of cells with
10 µM QH2 for 24 h. Thus, as shown in Figure 1A–C, the
LPS-induced responses were significantly decreased to
60.27 ± 9.3%, 48.13 ± 6.93% and 74.36 ± 7.25% for TNF-
α, MIP-1α and RANTES, respectively (Fig. 1A–C). No sig-
nificant effect was found for MCP-1 (Fig. 1D). Pre-
incubation of cells with 10 µM PDTC or 10 µM NAC
decreased TNF-α levels significantly to 47.69 ± 19.07%
and 54.43 ± 17.64%, respectively (Fig. 1A). No significant
effects of PDTC and NAC were found on LPS-induced
secretion levels of other pro-inflammatory mediators.
Inflammation has been related to the pathogenesis of
various diseases, such as atherosclerosis [13]. Monocytes
play an important role in the response to inflammatory
agents, particularly to those derived from gut bacteria and
are able to enter the circulation, such as bacterial endotoxins.
Thus, endotoxins circulate at low concentrations in the
blood of all healthy individuals, but are also increased after
a high-fat meal [14]. However, elevated levels are associated
with an increased risk of atherosclerosis or sepsis [14–16].
For our experiments we used LPS, a compound of gram-
negative bacteria that is also relevant in vivo to trigger a
serious medical inflammatory process in vitro. Finally,
stimulation of monocytes with LPS induces production of
ROS, which in turn activate the transcription factor NFκB
[4, 9] that triggers a large amount of genes encoding for
inflammatory mediators and cytokines [17]. Numerous
studies in monocytes revealed natural occurring antioxidants
as compounds with anti-inflammatory effects [18, 19].
Here we used CoQ10 in order to study its putative anti-
inflammatory effect in the human monocytic cell line THP-
1. For this purpose, we used the reduced form of CoQ10,
QH2, which functions as an antioxidant. To our knowledge,
effects of QH2 on inflammatory markers have not been
investigated so far, because this form of CoQ10 is not
commonly available. Thus, only a few studies were
published using QH2 in vivo. These studies indicate effects
Fig. 1. Effects of pre-treatment of ubiquinol on LPS-induced release of TNF-α (A), MIP-1α (B), RANTES (C) and MCP-1 (D) in
THP-1 cells.
Cells were either pre-treated with 10 µM QH2 or the respective reference substances PDTC or NAC, or medium and vehicle for
24 h. Afterwards, media were removed and cells were treated with LPS (1 µg/ml medium) for 4 h. The resulting concentrations
(pg/µg cellular protein) of TNF-α, MIP-1α, RANTES and MCP-1 of the vehicle controls (+LPS) were set to 100% for QH2-
pretreated cells and the other values were referenced to it. Values from PDTC- and NAC-pretreated cells were related to
medium controls (+LPS) taken as 100%. Statistically significant data (*, p≤0.05; **, p≤0.01; ***, p≤0.001) are means ± SEM
of four (ubiquinol, vehicle) or two (PDTC, NAC, medium) independent experiments performed in duplicate.
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of QH2 on safety and bioavailability [20], sperm kinetic
features [21], oxidative imbalance in children with Trisomy
21 [22] and neuroprotection in an animal Parkinson model
[23]. In THP-1 cells, we found that QH2 reduces signifi-
cantly the secretion of the pro-inflammatory agents TNF-α,
MIP-1α, and RANTES in response to LPS. This putative
anti-inflammatory effect of QH2 could be due to its anti-
oxidant property in cell membranes, because LPS-induced
ROS production occurs very closely to the membrane [4].
One important membrane-associated complex that is rele-
vant for generation of ROS in monocytic cells [24] is the
NADPH oxidase. This complex is described to consist of
four proteins, whereas Rac is the most critical component for
a functional NADPH oxidase. Rac is regulated by small
GTP-binding proteins [25]. In this context it was shown that
LPS induced Rac activity and moreover, the NADPH
oxidase-dependent ROS formation [26]. Thus it seems that
LPS directly initiates the NADPH oxidase activity by
downstream signalling pathways. Results from a further
study indicate an up-regulation of the NADPH oxidase
complex through a NFκB-dependent TNF-α activation
process which finally leads to enhanced ROS production
and further NFκB-activation [24]. This in turn might
contribute to sustained releases of pro-inflammatory cyto-
kines and mediators. In this context it was also shown that
the well known antioxidant and radical scavenger NAC
inhibited NFκB-activation via reduction of H2O2 [9], an
important reactive oxygen intermediate (ROI) of the
NADPH oxidase pathway. These strong radical scavenging
effects are also described for PDTC [27], which we used as
an additional internal control to describe the putative anti-
inflammatory effects of the reduced form of CoQ10 (QH2), a
compound with strong antioxidant properties. In general it
seems that QH2 mediates stronger anti-inflammatory effects
on the tested pro-inflammatory compounds than PDTC and
NAC, two well known radical scavengers mediating its
anti-inflammatory properties through a diminished NFκB
activation. Thus it seems that the reduced form of CoQ10
(QH2) mediates its anti-inflammatory effects at least in part
through its strong antioxidant properties. However, these
effects may be additionally mediated by gene expression. It
has been shown in skeletal muscle of humans [28], heart of
mice [29], CaCo-2 [30], and HeLa cells [31] that CoQ10
influences the expression of different genes. These hypo-
theses should be tested in future studies. In conclusion, our
results indicate anti-inflammatory effects of the reduced
form of CoQ10 on various proinflammatory cytokines and
chemokines in vitro.
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Our present study reveals significant decelerating effects on senescence processes in middle-aged
SAMP1 mice supplemented for 6 or 14 months with the reduced form (Q10H2, 500mg/kg BW/
day) of coenzyme Q10 (CoQ10). To unravel molecular mechanisms of these CoQ10 effects, a
genome-wide transcript profiling in liver, heart, brain and kidney of SAMP1 mice supplemented
with the reduced (Q10H2) or oxidized form of CoQ10 (Q10) was performed. Liver seems to be the
main target tissue of CoQ10 intervention, followed by kidney, heart and brain. Stringent
evaluation of the resulting data revealed that Q10H2 has a stronger impact on gene expression
than Q10, primarily due to differences in the bioavailability. Indeed, Q10H2 supplementation was
more effective than Q10 to increase levels of CoQ10 in the liver of SAMP1 mice. To identify
functional and regulatory connections of the ‘‘top 50’’ (po0.05) Q10H2-sensitive transcripts in
liver, text mining analysis was used. Hereby, we identified Q10H2-sensitive genes which are
regulated by peroxisome proliferator-activated receptor-a and are primarily involved in cholesterol
synthesis (e.g. HMGCS1, HMGCL and HMGCR), fat assimilation (FABP5), lipoprotein meta-
bolism (PLTP) and inflammation (STAT-1). These data may explain, at least in part, the decel-
erating effects on degenerative processes observed in Q10H2-supplemented SAMP1 mice.
Keywords:
CoQ10 / Gene expression / Inflammation / Lipid metabolism / peroxisome
proliferator-activated receptor-a
1 Introduction
Coenzyme Q10 (CoQ10) is an essential cofactor in the elec-
tron transport chain, serves as a potent antioxidant in lipid
membranes and is a cofactor of uncoupling proteins. More
recently, we identified CoQ10 as a compound with anti-
inflammatory properties in vitro [1, 2]. These effects are
thought to be mediated through gene expression and/or the
radical scavenging activity of the reduced form of CoQ10
(Q10H2) [3, 4]. Moreover, Q10H2 also indicated stronger anti-
inflammatory effects than the oxidized form (Q10) in vitro.
From these data, different effects of the oxidized and
reduced form of CoQ10 on redox-dependent gene expression
patterns were hypothesized. Very recently, we provide
evidence in vitro and in mice that Q10H2 modulates the
expression of the anti-inflammatory microRNA-146a [5].
The senescence-accelerated mice is a well-established model
to study the aging process in higher organisms [6, 7]. SAMP
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strains grow normally but show early signs of aging including,
e.g. reduced physical activity, loss of hair glossiness and shorter
life span [8]. Analysis of aging dynamics, based on survival
curves, senescence scores and growth rate, shows that the
aging pattern in SAMP strains is characterized by accelerated
senescence after normal development [8, 9]. Because SAMP1
mice show also a high oxidative stress status [10, 11], they are a
suitable model to study putative effects of antioxidants such as
CoQ10 on physiological and molecular readouts. Our present
study shows significant reducing effects on accelerated senes-
cence processes in SAMP1 mice supplemented with Q10H2.
To get insight into the molecular mechanisms of these effects,
we studied the influence of Q10 as well as Q10H2 on gene
expression in liver, heart, brain and kidney of SAMP1 mice.
2 Materials and methods
2.1 Animals
SAMP1 mice were reared in the Division of Laboratory
Animal Research, Research Center for Human and Envir-
onmental Sciences, Shinshu University, under specific
pathogen-free conditions at 24721C and a 12-h light–dark
cycle. Water and food intake were available ad libitum. At the
beginning of the long-term controlled study, 4-wk-old female
SAMP1 mice were purchased from Japan SLC (Hamamatsu,
Japan) and housed 3–6 per cage (20 cm wide, 30 cm long,
10 cm deep). Grouping of the animals remained unchanged
throughout the study. Body weights, food intake and degree
of senescence were calculated monthly while mice were
inspected daily. Animals were sacrificed by cardiac puncture
under anaesthesia with diethyl ether after 6 or 14 months of
Q10H2 or Q10 supplementation. Organs (liver, heart, brain
and kidney) were removed and stored at –801C until RNA
isolation. Study protocol and experimental procedures were
approved by the ethics committee of Shinshu University.
2.2 Evaluation of degree of senescence
The degree of senescence was evaluated by a grading system [9].
Eleven categories of behavioral activity and gross appearances of
the skin, eyes, and spine were considered to be associated with
the aging process: each category was graded 0 to 4 according to
the degree of change, and the grading score for each mouse
was the sum of the grades of each category. Generally, the
grading was done at a fixed time (from 2 pm to 4 pm) by an
observer who was blinded to the treatment of the mice.
2.3 Q10H2 and Q10 supplementation and preparation
of the diet
In the initial phase of the experiment, SAMP1 mice
were randomly assigned to three groups: Q10H2
animals (n5 22), Q10 animals (n5 11) or control animals
(n5 20).
The oxidized (Q10) or reduced form (Q10H2) of CoQ10 was
added to a standard laboratory mouse diet (powdered CE-2,
CLEA Japan) using corn oil (1%, v/w) as a vehicle and to
achieve a final concentration of Q10 or Q10H2 of 0.5%,
respectively. The control diet was prepared using corn oil
only. The mixture was incorporated in pellet-type chow by
adding 30%v/v ethanol solution, pressure shaping and
drying. Storage of the diet was conducted at –201C for up to
4wk before administration.
2.4 Determination of total CoQ10 and its redox state
in liver samples of 14M SAMP1 mice
Total levels and redox state of CoQ10 (Q10H2, Q10) were
determined in liver homogenates of 14M intervention
(Q10H2, Q10) and control mice (n5 3 per each group). The
method is based on HPLC analysis with electrochemical
detection with minor modifications as described before [12].
In brief, 1.95mL of 2-propanol was added to 50mg liver
sample and mixed with a Polytron homogenizer. Subse-
quently, the homogenate was diluted 15-fold with 2-propa-
nol. After centrifugation (9500 g, 3min, 41C), 50 mL of the
supernatant was injected into the HPLC system.
The mobile phase consisted of 0.05M sodium perchlorate
in methanol/hexane (88:12 v/v) at a flow rate of 1.0mL/min.
The oxidation potential of the ECD was 600mV (versus Ag/
AgCl). Q10H2 and Q10 levels were quantified by an external
standard method based on peak area.
2.5 Isolation of mRNA from mice tissue for
microarray analysis
Total RNA was extracted from mice tissues (n5 3 per each
group) with the following kits (all from Qiagen, Japan)
according to the manufacturer’s instructions: RNeasy Kit
(for liver and kidney), RNeasy Fibrous Tissue Mini Kit (for
heart) and RNeasy Lipid Tissue Mini Kit (for brain).
2.6 Expression profiling
Microarray analysis was conducted on three samples for
each group, respectively, by using GeneChips Mouse
Genome 430 2.0 Array (Affymetrix) containing Q145 100 probe
sets. The procedure was performed according to the
manufacturer’s instructions using Poly-A RNA Control Kit
(Affymetrix) and One-Cycle cDNA Synthesis Kit (Affyme-
trix) for cDNA synthesis, Sample Cleanup Module (Affy-
metrix) for purification, and IVT Labeling Kit (Affymetrix)
for synthesis of biotin-labeled cRNA. Fifteen micrograms of
fragmented cRNA was hybridized to a Mouse Genome 430
2.0 Array for 16 h at 451C at 60 rpm. After hybridization,
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arrays were washed on GeneChips Fluidics station 450
(Affymetrix) and stained with streptavidin–phycoerythrin.
Thereafter, microarrays were scanned with a GeneChips
Scanner 3000 7G (Affymetrix). Expression data were
normalized with Affymetrix GeneChip Operating Software
1.4 using mean value (global normalization). Only probe
sets showing present calls for all three arrays at one
experimental group (intervention or control) were consid-
ered for further analysis. The accession number for the
complete datasets submitted to NCBI Gene Expression
Omnibus is GSE15129 (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc5GSE15129).
2.7 Text-mining study
2.7.1 Genomatix bibliosphere
Genomatix Software 2008 (www.genomatix.de) was
used to perform text-mining analysis. The probe set IDs
of the Q10H2-regulated genes were uploaded to Biblio-
spherePathwayEdition Software. This text-mining tool
identifies putative functional connections based on co-cita-
tions of gene names and synonyms from NCBI Pubmed
[13]. The co-citation filter ‘‘geneyfunction wordygene’’
(GFG level B3) was applied.
2.8 Statistics
Results were analyzed by an unpaired, two-sided Student’s
t-test using SPSS 11.5 for Windows and GraphPad Prism
4.0 software. p-Values less than or equal to 0.05 were
considered statistically significant.
3 Results
3.1 Effects of Q10H2- and Q10-supplementation on
food intake and grading score of senescence in
SAMP1 mice
Food intake of SAMP1 mice was calculated monthly and no
difference in food consumption was apparent among the
three groups (control, Q10H2 and Q10). Based on mean food
intake (3.4 g/d) and mean body weight (33 g), mice
consumed 500mg/kg BW/d Q10H2 or Q10, respectively. No
differences in body weight were found between Q10H2 and
Q10 supplemented animals. Senescence grading scores
increased from 16 or 20wk of age in SAMP1 mice
of all groups (Q10H2, Q10 and control). However, grading
scores in the Q10H2 group were lower than in Q10- and
control-treated mice. There was a significant difference
between control and Q10H2 mice from 16 to 68wk of age
(po0.05) (Fig. 1). This result was also found in previous
experiments [14].
3.2 Effects of Q10H2- and Q10-supplementation on
whole genome expression profiles in different
tissues of SAMP1 mice
Microarray-based whole genome expression profiles were
analyzed from liver, heart, brain and kidney of SAMP1 mice
supplemented with Q10H2, Q10 or a control diet. From every
experimental group, six mice per each group were sacrificed
at 6 and 14 months (three mice at each time point, respec-
tively) after supplementation, resulting in a total of 72
microarrays. Differentially expressed genes in tissues of
SAMP1 mice treated with Q10H2 or Q10 were selected as
follows. First, transcripts with at least three present calls in
one group (intervention versus control) were chosen for
further analysis. Second, transcripts showing at least a 1.5-
fold increase or decrease in the Q10H2 or Q10 groups versus
control animals at po0.05 by Student’s t-test, or alter-
natively, a 1.3-fold increase or decrease at po0.01, were
selected. Third, only those transcripts were referred to as
Q10H2- and/or Q10-sensitive having been significantly
expressed in at least three different tissues, or alternatively,
in two tissues at different time points or with a fold-change
level of at leastZI1.5I at po0.01 (Tables 1 and 2). Based on
these stringent criteria, 20 and 3 transcripts were identified
as Q10H2- or Q10-sensitive, respectively (Table 1). Most
Q10H2-sensitive transcripts were differentially expressed in
liver and kidney at 6 or 14 months after supplementation.
Moreover, 17 transcripts were identified to be regulated by
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Figure 1. Age-related change on senescence grading scores in
SAMP1 mice supplemented with Q10H2, Q10 or vehicle control.
SAMP1 mice were supplemented with either Q10H2 or Q10
(500mg/kg BW/d), or a respective control diet for 14 months.
Senescence grading scores increased from 16 or 20wk of age in
SAMP1 mice of all groups (Q10H2, Q10, control). Grading scores
in the Q10H2 group were lower than in Q10 and control mice.
There was a significant difference (po0.05) between control and
Q10H2 mice from 16 to 60wk of age (po0.05). However, no
significant differences were found for Q10-treated animals when
compared with controls.
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Q10H2 as well as Q10 treatment (Tables 2 and 3). These
transcripts were designated as ‘‘CoQ10-sensitive.’’ As shown
in Tables 2 and 3, 14 CoQ10-sensitive transcripts were
differentially expressed in the kidney at 6 months but not at
14 months after supplementation with Q10 and Q10H2. In
the liver, 16 CoQ10-sensitive transcripts were affected by Q10
at 14 months after supplementation. In contrast, Q10H2
affected most of these genes at 6 months after supple-
mentation. Taken together, our data in SAMP1 mice
suggested that liver and kidney are the main target tissues of
Q10H2 or Q10 intervention regarding gene expression.
Furthermore, Q10H2 may have stronger impact on gene
expression. In accordance to this hypothesis, Q10H2-sensi-
tive transcripts (liver, 14M supplemented) which suggest
stronger regulatory effects (‘‘Top 10,’’ po0.05) are char-
acterized by higher expression fold-change values in
comparison to Q10-sensitive transcripts (Tables 4 and 5).
3.3 Detailed analysis of gene expression data
obtained from liver samples of Q10H2-
supplemented SAMP1 mice
With regard to the effects of Q10H2 and Q10 on gene
expression in different tissues of SAMP1 mice, liver was
shown to be strongly affected. Regarding the senescence
deceleration process in SAMP1 mice, Q10H2 was more
effective than Q10 (Fig. 1). This was also shown by a
previous study [14]. To study long-term effects of Q10H2-
supplementation on gene expression in more detail, liver
samples of Q10H2-supplemented animals (14M) were used.
Initially, up and downregulated Q10H2-sensitive transcripts
displaying the highest fold-change values (‘‘Top 50,’’
po0.05) were selected. To unravel the functional connec-
tions of these genes we performed a text mining approach
using the Genomatix BibliospherePathwayEdition Software
1
3
5
7
9
11
13
15
17
19
21
23
25
27
29
31
33
35
37
39
41
43
45
47
49
51
53
55
1
3
5
7
9
11
13
15
17
19
21
23
25
27
29
31
33
35
37
39
41
43
45
47
49
51
53
55
Table 1. Expression profiles of Q10H2- and Q10-sensitive transcripts in different tissues
Fold change Q10H2
Liver Heart Brain Kidney
Gene
ID
6M 14M 6M 14M 6M 14M 6M 14M Gene name
228880 1.74 2.15 RIKEN CDNA 2010005I16 GENE
217232 2.10 1.86 1.45 CELL DIVISION CYCLE 27 HOMOLOG (S. CEREVISIAE)
17979 3.64 2.16 1.59 NUCLEAR RECEPTOR COACTIVATOR 3
108962 2.21 1.76 1.68 RIKEN CDNA 4833441D16 GENE
20481 3.67 2.36 SLOAN-KETTERING VIRAL ONCOGENE HOMOLOG
72949 3.21 1.82 1.82 CYCLIN T2
170942 2.60 1.91 1.96 1.56 ERYTHROID DIFFERENTIATION REGULATOR 1
100910 2.10 2.18 1.70 RIKEN CDNA 2010209O12 GENE
66277 1.70 1.59 KRUPPEL-LIKE FACTOR 15
21413 3.19 1.75 1.77 TRANSCRIPTION FACTOR 4
84092 2.28 2.97 1.56 PUTATIVE DEUBIQUITINATING ENZYME
56490 3.53 1.82 ZINC FINGER AND BTB DOMAIN CONTAINING 20
NA 2.31 1.69 1.72 NA
94112 2.93 2.17 1.69 POSITIVE COFACTOR 2, MULTIPROTEIN COMPLEX,
GLUTAMINE/Q-RICH-ASSOCIATED PROTEIN
170942 2.26 2.02 1.51 ERYTHROID DIFFERENTIATION REGULATOR 1
NA 2.41 2.60 NA
319885 2.13 1.82 1.83 ZINC FINGER, CCHC DOMAIN CONTAINING 7
67039 2.17 2.60 2.0 1.66 RIKEN CDNA 2600011C06 GENE
52680 1.88 1.73 1.53 DNA SEGMENT, CHR 13, ERATO DOI 787, EXPRESSED
27981 1.95 2.01 DNA SEGMENT, CHR 4, WAYNE STATE UNIVERSITY 53,
EXPRESSED
Fold change Q10
Liver Heart Brain Kidney
Gene
ID
6M 14M 6M 14M 6M 14M 6M 14M Gene name
15511 3.67 2.17 4.14 HEAT SHOCK PROTEIN 1B
94089 2.17 3.63 TRIPARTITE MOTIF PROTEIN 7
76044 1.69 1.69 1.66 LEUCINE ZIPPER PROTEIN 5
pr0.05, pr0.01
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Table 2. Expression profiles of transcripts both sensitive for Q10H2 and Q10 in different tissues: fold change Q10H2
Fold change Q10H2
Liver Heart Brain Kidney
Gene
ID
6M 14M 6M 14M 6M 14M 6M 14M Gene name
63830# 3.34# 3.87 2.31# KCNQ1 OVERLAPPING TRANSCRIPT 1
552902 1.67 1.92 HYPOTHETICAL LOC552902
68186 2.87 2.03 RIKEN CDNA 4632427E13 GENE
233489 2.43 PHOSPHATIDYLINOSITOL BINDING CLATHRIN ASSEMBLY
PROTEIN
78265 2.92 2.57 RIKEN CDNA 4632418H02 GENE
27981 2.12 2.61 DNA SEGMENT, CHR 4, WAYNE STATE UNIVERSITY 53,
EXPRESSED
68371 3.41 1.91 RIKEN CDNA 0610038K03 GENE
96982 3.48 1.85 EXPRESSED SEQUENCE C79248
76719 2.51 1.92 RIKEN CDNA 1700081L11 GENE
319263 2.61 1.59 1.52 1.66 PROTEIN-L-ISOASPARTATE (D-ASPARTATE) O-
METHYLTRANSFERASE DOMAIN CONTAINING 1
20239 2.00 1.60 ATAXIN 2
208618 4.26 1.87 CDNA SEQUENCE BC026657
108829 2.40 1.66 JUMONJI DOMAIN CONTAINING 1C
622943 1.67 2.24 DNA SEGMENT, CHR 5, ERATO DOI 579, EXPRESSED
320861 4.15 1.60 RIKEN CDNA C130047D21 GENE
13196 2.21 2.01 DEVELOPMENT AND DIFFERENTIATION ENHANCING
72739 2.41 2.43 ZINC FINGER PROTEIN 306
pr0.05, pr0.01, #presented byZ2 probe set IDs.
Table 3. Expression profiles of transcripts both sensitive for Q10H2 and Q10 in different tissues: fold change Q10
Fold change Q10
Liver Heart Brain Kidney
Gene
ID
6M 14M 6M 14M 6M 14M 6M 14M Gene name
63830# 1.64 3.07 KCNQ1 OVERLAPPING TRANSCRIPT 1
552902 1.89 1.71 HYPOTHETICAL LOC552902
68186 1.51 2.04 RIKEN CDNA 4632427E13 GENE
233489 2.59 2.79 PHOSPHATIDYLINOSITOL BINDING CLATHRIN ASSEMBLY PROTEIN
78265 1.86 3.34 RIKEN CDNA 4632418H02 GENE
27981 2.31 2.23 DNA SEGMENT, CHR 4, WAYNE STATE UNIVERSITY 53, EXPRESSED
68371 1.90 1.54 RIKEN CDNA 0610038K03 GENE
96982 1.73 2.18 EXPRESSED SEQUENCE C79248
76719 1.51 1.95 RIKEN CDNA 1700081L11 GENE
319263 2.03 1.53 PROTEIN-L-ISOASPARTATE (D-ASPARTATE) O-
METHYLTRANSFERASE DOMAIN CONTAINING 1
20239 2.53 1.92 ATAXIN 2
208618 2.46 1.71 CDNA SEQUENCE BC026657
108829 1.77 2.08 JUMONJI DOMAIN CONTAINING 1C
622943 1.94 2.51 DNA SEGMENT, CHR 5, ERATO DOI 579, EXPRESSED
320861 2.25 1.54 RIKEN CDNA C130047D21 GENE
13196 1.66 1.84 DEVELOPMENT AND DIFFERENTIATION ENHANCING
72739 1.77 2.57 ZINC FINGER PROTEIN 306
pr0.05, pr0.01, #presented byZ2 probe set IDs.
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(GFG level B3). Co-cited transcripts having been repre-
sented by multiple probe sets for one gene and/or were
shown by high intensity levels were selected. Based on these
criteria, we identified 11 Q10H2-sensitive transcripts which
seem to be primarily involved in cholesterol and lipid
metabolism as well as in inflammatory processes and cell
differentiation (Table 6). Moreover, a part of the identified
Q10H2-sensitive genes is functionally connected by the
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Table 4. ‘‘Top 10’’ of up- and down-regulated Q10H2-regulated transcripts in the liver of SAMP1 mice (14M)
Gene ID FC Gene symbol Gene name
Upregulated
21822 21.24 TGTP T-CELL SPECIFIC GTPASE
27007 14.18 KLRK1 KILLER CELL LECTIN-LIKE RECEPTOR SUBFAMILY K, MEMBER 1
18439 12.52 P2RX7 PURINERGIC RECEPTOR P2X, LIGAND-GATED ION CHANNEL, 7
19363 12.07 RAD51L1 RAD51-LIKE 1 (S. CEREVISIAE)
328563 10.68 APOL11B RIKEN CDNA A330102K04 GENE
22368 9.68 TRPV2 TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY V, MEMBER 2
328563 9.55 APOL11B RIKEN CDNA A330102K04 GENE
20846 9.21 STAT1 SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1
11801 9.11 CD5L CD5 ANTIGEN-LIKE
14131 8.87 FCGR3 FC RECEPTOR, IGG, LOW AFFINITY III
Downregulated
17840# 6.12 MUP1 MAJOR URINARY PROTEIN 1
56631 4.60 TRIM17 TRIPARTITE MOTIF PROTEIN 17
18113 4.16 NNMT NICOTINAMIDE N-METHYLTRANSFERASE
23985 4.16 SLC26A4 SOLUTE CARRIER FAMILY 26, MEMBER 4
13089 3.47 CYP2B13 CYTOCHROME P450, FAMILY 2, SUBFAMILY B, POLYPEPTIDE 13
78894 3.40 AACS ACETOACETYL-COA SYNTHETASE
76574 3.38 MFSD2 MAJOR FACILITATOR SUPERFAMILY DOMAIN CONTAINING 2
17844 3.30 MUP5 MAJOR URINARY PROTEIN 5
53901 3.27 RCAN2 DOWN SYNDROME CRITICAL REGION GENE 1-LIKE 1
13897 3.26 ES22 ESTERASE 22
pr0.05, pr0.01, #presented byZ2 probe set IDs.
Table 5. ‘‘Top 10’’ of Q10 up and downregulated transcripts in the liver of SAMP1 mice (14M)
Gene ID FC Gene symbol Gene name
Upregulated
70945 7.15 MMRN1 MULTIMERIN 1
NA 5.37 NA NA
207921 4.48 A830093I24RIK RIKEN CDNA A830093I24 GENE
381280 4.19 6430706D22RIK RIKEN CDNA 6430706D22 GENE
217166 4.00 NR1D1 NUCLEAR RECEPTOR SUBFAMILY 1, GROUP D, MEMBER 1
15511 3.90 HSPA1B HEAT SHOCK PROTEIN 1B
52822 3.86 RUFY3 RUN AND FYVE DOMAIN CONTAINING 3
71972 3.85 DNMBP RIKEN CDNA 2410003L07 GENE
67039 3.84 RBM25 RIKEN CDNA 2600011C06 GENE
11430 3.78 ACOX1 ACYL-COENZYME A OXIDASE 1, PALMITOYL
Downregulated
12592 5.13 CDX4 CAUDAL TYPE HOMEO BOX 4
16625 3.90 SERPINA3C SERINE (OR CYSTEINE) PEPTIDASE INHIBITOR, CLADE A, MEMBER 3C
14803 3.09 GRID1 GLUTAMATE RECEPTOR, IONOTROPIC, DELTA 1
233987 2.38 BC003267 CDNA SEQUENCE BC003267
22648 2.33 ZFP11 ZINC FINGER PROTEIN 11
75458 2.30 CMTM2A RIKEN CDNA 1700001K04 GENE
66658 2.21 CCDC51 COILED-COIL DOMAIN CONTAINING 51
216805 2.18 FLCN FOLLICULIN
81011 2.15 V1RD14 VOMERONASAL 1 RECEPTOR, D14
75424 2.04 ZFP820 HYPOTHETICAL GENE MGC29393
pr0.05, pr0.01.
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peroxisome proliferator-activated receptor-a (PPAR-a)
signaling pathway (Fig. 2).
3.4 Accumulation of CoQ10 in liver samples of
Q10H2- and Q10-supplemented SAMP1 mice
Next, we tested whether CoQ10 accumulates in the liver of
SAMP1 mice supplemented for 14 months with Q10H2 or
Q10. Total CoQ10 as well as its redox state was determined in
liver homogenates of SAMP1 mice which were used for
microarray experiments (n5 3 per each group). In compar-
ison to control animals, total CoQ10 levels increased about
54.92-fold (p5 0.0027) and 30.36-fold (p5 0.0006) in the
liver of Q10H2- and Q10-supplemented mice, respectively
(Fig. 3A). As shown in Figs. 3B and C, 77.53% (Q10H2-
supplemented) and 80.72% (Q10H2-supplemented) of CoQ10
was present in its reduced form. Because CoQ9 is the
predominant CoQ form in rodents [15], CoQ9 levels were
additionally determined in liver samples. As shown in
Fig. 3D, the CoQ9 concentration did not significantly change
between treatment and control groups. In conclusion,
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Table 6. Identification of Q10H2-sensitive genes and their functional connections
FC
Gene ID Q10H2 Q10 Gene symbol Gene name
Fatty acid and cholesterol synthesis
208715# 1.68 n.s. HmgCs1 3-Hydroxy-3-methylglutaryl-coenzyme A synthase 1
15356 1.40 n.s. HmgCl 3-Hydroxy-3-methylglutaryl-coenzyme A lyase
15357 2.44 n.s. HmgCr 3-Hydroxy-3-methylglutaryl-coenzyme A reductase
78894 3.40 n.s. Aacs Acetoacetyl-CoA Synthetase
20787 1.97 1.52 Srebf1 Sterol regulatory element-binding factor-1
Lipid mobilization
16592# 3.63 n.s. Fabp5 Fatty acid binding protein 5, epidermal
Lipoprotein metabolism
18830# 8.30 n.s. Pltp Phospholipid transfer protein
Inflammation
20846 9.21 n.s. Stat1 Signal transducer and activator of transcription 1
Cell differentiation and activation
75104# 3.17 n.s. Mmd2 Monocyte to macrophage differentiation-associated 2
17476 7.20 n.s. Mpeg1 Macrophage-expressed gene 1
100702 5.74 n.s. Mpa2l Macrophage activation-2 like
pr0.05, pr0.01, #presented byZ2 probe set IDs.
Figure 2. Bibliosphere network of Q10H2-
sensitive genes regulated in the liver of
SAMP1 mice. Based on co-citations with
transcription factors and functional co-cita-
tions with other genes in the network (GFG
level B3), 5 Q10H2-inducible genes were
connected with each other by Biblio-
spherePathwayEdition Software. According
to this, the uploaded genes seem to play a
key role in PPAR-a signaling. IN, input gene;
TF, transcription factor; M, gene product is
part of a metabolic pathway; ST, gene
product is part of a Genomatix signal trans-
duction pathway.
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Q10H2 supplementation was more effective than Q10 to
increase the absolute levels of Q10H2 and Q10 in the liver of
SAMP1 mice. Thereby, Q10H2 was the predominant form of
CoQ10 in liver tissues.
4 Discussion
Data from previous [14] and present experiments reveal
significant effects on decelerated senescence processes in
SAMP1 mice supplemented with Q10H2 (Fig. 1). Addition-
ally, distinct differences in gene expression profiles of
Q10H2- and Q10-supplemented SAMP1 mice in liver, heart,
brain and kidney were identified. Because the oxidized form
of CoQ10 can be reduced to Q10H2 by the plasma membrane
redox system [16, 17], different effects of Q10H2 and Q10 on
aging processes and gene expression are not obvious.
However, the conversion of Q10 to Q10H2 is accompanied by
the generation of reactive oxygen species [18],] which affects
cellular redox-dependent gene regulation cascades [19]. A
study in platelets also indicated a less effectiveness of the
oxidized form of CoQ10 on oxidative stress parameters,
despite the presence of quinone reductase activities [20].
Indeed, the activity of the plasma membrane redox system is
modulated by different conditions including oxidative stress
and aging [21, 22]. However, studies in perfused rat liver and
isolated rat hepatocytes clearly indicated an antioxidant
effect of exogenous Q10H2 [23, 24]. Some studies also
reported about age-related decreases of CoQ10 levels in
organs of both rates and humans [25]. In general, aging is
considered as a process that seems to require an increase of
antioxidant defenses to cope enhanced oxidative stress
conditions [26, 27]. Additionally, differences in the tissue-
dependent bioavailability of Q10H2 and Q10 may also have
an impact on gene expression. Indeed, we found that Q10H2
supplementation was more effective than Q10 to increase
levels of CoQ10 in the liver of SAMP1 mice. This might be in
agreement with our previous results in monocytic cell lines,
where incubation with raising doses of Q10H2 also induced a
dose-dependent increase of the intracellular Q10H2/Q10 ratio
[5] when compared with Q10 incubation [1]. This Q10H2-
specific effect additionally reveals the effectiveness of the
exerted Q10H2 storage conditions for in vitro and in vivo
studies. With regard to our present study, liver seems to be
the main target tissue of CoQ10 intervention regarding gene
expression, followed by kidney, heart and brain. This might
be due to the fact that CoQ10 is mainly incorporated in LDL
[28],] which are taken up by the liver. In this context, it was
also shown that CoQ10 is capable to prevent LDL particles
from oxidation in vitro and in vivo [29–32]. This effect is
considered to be mediated through the radical scavenging
activity of the reduced form of CoQ10, at least in part by the
regeneration of tocopheryl radicals [31, 33–35]. In this
context our preliminary data (unpublished results) from
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Figure 3. Effect of Q10 and Q10H2 supplementation on levels of total CoQ10 (A), redox status (B, C) and CoQ9 (D) in liver tissues of SAMP1
mice. SAMP1-mice were supplemented with either Q10H2 or Q10 (500mg/kg BW/d), or a respective control diet for 14 months. Thereafter,
liver samples were collected, homogenized and used for HPLC analysis. Total CoQ10 levels increased about 54.92-fold (p5 0.0027) and
30.36-fold (p5 0.0006) in liver tissues of Q10H2- and Q10-supplemented mice (A). Supplementation with Q10H2 and Q10 increased Q10H2
levels significantly about 47.86-fold (p5 0.0054) and 27.54-fold (p50.0003), respectively (B). Q10H2 supplementation induces also the
strongest increase of Q10 levels in liver when related to controls (112.10-fold, p5 0.0019) (C). The CoQ9 level did not significantly change
between treatment and control groups (D). All data are means7SEM of three animals per each group (Q10H2, Q10, control), respectively.
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another study in mice (C57BL6J) revealed a significant
reduction (about 45711.9%, p5 0.0140) of the pro-inflam-
matory chemokine MCP-1 in Q10H2 supplemented animals.
The observed consistence of CoQ9 levels in tissue
samples of CoQ10 supplemented mice were already descri-
bed before [33].
With regard to gene expression data, a detailed analysis of
whole genome expression profiles was performed for liver
samples of mice supplemented with Q10H2 for 14 months.
The results of the applied text-mining tool indicate an
involvement of Q10H2-sensitive genes in the PPAR-a
signaling pathway (Fig. 2). PPARs belong to the group of
nuclear receptors and are negative regulators of numerous
genes involved in lipid metabolism and cholesterol synthesis
[36–40]. Moreover, it was shown that PPAR-a is predomi-
nantly expressed in tissues with high lipid catabolic activity
[37]. In this context we identified a number of genes
(Table 6) strongly downregulated by Q10H2-supplementa-
tion in the liver of SAMP1 mice. These genes were primarily
involved in fatty acid and cholesterol synthesis (e.g.
HMGCS1, HMGCL and HMGCR), lipid metabolism
(FABP5) as well as lipoprotein metabolism (PLTP). More-
over, a regulatory role of PPAR-a in lipid metabolism and
inflammatory processes is indicated in the literature [41–45].
The activation of PPAR-a occurs through, e.g. fatty acids and
fibrates, a known class of hypolipidemic drugs. PPAR-a
forms a heterodimer with retinoid X receptor (RXR)
enhancing its binding to DNA sequence elements termed
peroxisome proliferator response elements (PPRE) [46].
Liver X receptor (LXR) was found to inhibit the binding of
the PPAR-a-9-cis retinoic acid receptor (PPAR-a/RXR)
complex to PPRE [37]. Thus, ligand binding of LXR inhibits
PPAR-a signaling and the activation of its downstream-
target genes. Because LXR is activated by oxidized sterol and
cholesterol metabolites [47, 48], antioxidant compounds
might effectively inhibit activated LXR/RXR hetero-
dimerization. Based on this data, we propose three putative
functions for Q10H2 in PPAR-a-mediated signaling proces-
ses (Fig. 4): (i) as an antioxidant, leading to decreased levels
of the LXR agonist oxidized LDL; (ii) as an antagonist of
LXR, leading to PPAR-a/RXR heterodimers and PPRE
activation; and (iii) as an agonist of PPAR-a, leading to
PPAR-a/RXR heterodimers and PPRE activation. Moreover,
the protein product of the Sterol regulatory element binding
transcription factor-1 gene (SREBF-1, SREBP-1), described
as a primary target gene of the RXR/LXR heterodimer
[48, 49], was downregulated in liver samples of Q10H2-
supplemented animals (Table 6). This might be a first
indication of a Q10H2-mediated effect on PPAR-a signaling
that leads to a reduced activation of the SREBF-1 promoter, a
transcription factor that is known to activate fatty acid
synthesis by increasing transcription of lipogenic genes
[50–52]. Data of a recent study also demonstrate effects of
CoQ10 treatment on lipid metabolism in obese ob/ob mice
[53]. These effects were supposed to be mediated by PPAR-
mediated activity. Moreover, a connection between PPAR-a
signaling, inflammatory processes and neurodegenerative
diseases in aging rats has been previously described [54].
These metabolic effects may explain, at least in part, the
observed diminished effects on senescence characteristics in
Q10H2-supplemented SAMP1 mice. Noteworhty is that the
identified regulation of PPAR-a related genes observed in
Q10H2-supplemented SAMP1 mice was not found in liver
samples of Q10-supplemented mice, indicating a Q10H2-
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Figure 4. Putative mechanisms of Q10H2
action on PPAR-a signaling in liver tissues
of SAMP1 mice. Three putative functions
are proposed for Q10H2 in PPAR-a signal-
ing: 1. As an antioxidant, leading to
decreased levels of the LXR agonist
oxidized LDL; 2. As an antagonist of LXR,
leading to PPAR-a/RXR heterodimers and
PPRE activation; and 3. As an agonist of
PPAR-a, leading to PPAR-a/RXR hetero-
dimers and PPRE activation.
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specific effect. Hence, between Q10H2 and control animals,
no differences in expression levels of PPAR-a have been
identified (fold-change: 1.06, p5 0.827). This might be a
further hint for a Q10H2-modulatory effect on PPAR-a at the
protein level, the most important mechanism of transcrip-
tion factor regulation.
Even if the exact mechanism of Q10H2-PPAR-a interac-
tion cascades is not definitely clear, these results support our
conclusions regarding a regulatory role of Q10H2 in PPAR-a
signaling processes.
The authors have declared no conflict of interest.
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Abstract 
Previous in vitro studies indicate a role of Coenzyme Q10 (CoQ10) in gene 
expression, inflammation and apoptosis. To determine these effects in humans, a 
2-week supplementation study with the reduced form of CoQ10 (Q10H2, 150 mg/d) 
was performed in 53 healthy male volunteers. Mean CoQ10 plasma levels 
increased significantly (4.8-fold) after supplementation. Gene expression studies in 
isolated monocytes of study subjects revealed 7 Q10H2-sensitive genes (TNFα, 
CXCL2, CCL3, GIMAP7, NR4A2, BRE and PMAIP1) that are related to 
inflammation and apoptosis. These genes are functionally connected by NFκB and 
PPAR signalling pathways, which are involved in the regulation of lipid metabolism 
and cell differentiation. Biochemical as well as NMR-based analyses showed a 
significant reduction of LDL cholesterol plasma levels after Q10H2 supplementation. 
At the cellular level, we obtained alterations of haematological parameters 
including a reduced count of erythrocytes but an increased number of reticulocytes.  
In conclusion, Q10H2-supplementation reduces LDL cholesterol and affects cell 
differentiation processes in humans. These effects are hypothesized to be 
mediated by the antioxidant property of Q10H2 through NFκB and PPARα 
dependent gene expression cascades. 
 
  3 
Introduction 
Coenzyme Q10 (CoQ10) acts as a cofactor in the electron transport in the 
respiratory chain [1,2] and is required for the biosynthesis of pyrimidine nucleotides 
[3] and the function of uncoupling proteins (UCPs) [4]. More recently, CoQ10 has 
been identified as a modulator of gene expression in vitro [5] and in mice [6-8]. 
Moreover, our group and others observed anti-inflammatory [9-11] and anti-
apoptotic [12-16] effects of CoQ10 in vitro. These effects are hypothesized to be 
mediated by the antioxidant properties of the reduced form of CoQ10 (Q10H2) [2]. To 
reveal putative gene-regulatory effects of Q10H2 on inflammatory processes and 
apoptosis in vivo, 53 healthy male volunteers were supplemented with Q10H2 (150 
mg/d) for 2 weeks. So far, CoQ10 supplementation studies in a healthy study 
population are deficient when compared to those performed in diseased study 
groups, e.g. those with cardiovascular disorders [17]. Moreover, most published 
studies used oxidized CoQ10 (Q10) [18-21]. Although Q10 can be enzymatically 
converted into its reduced form (Q10H2) [22], our previous results in the monocytic 
cell line THP-1 indicated stronger anti-inflammatory effects of Q10H2 when 
compared to Q10 [9,10]. Additionally, the conversion of Q10 to Q10H2 is 
accompanied by the generation of reactive oxygen species (ROS) [23], with an 
additional impact on gene expression. In fact, it has been shown that reactive 
oxygen species (ROS) such as hydrogen peroxide (H2O2) are effective modulators 
of apoptotic processes by acting through gene expression [24,25]. Because 
monocytic cells have been described as key players in a variety of inflammatory 
and apoptotic processes [26-29], isolated monocytes were used for our gene 
expression studies.  
To our knowledge, this is the first study investigating gene-regulatory effects of the 
reduced form of CoQ10 (Q10H2) on inflammatory and apoptotic processes in a 
healthy study population. 
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Subjects and Methods 
 
Q10H2 formulation 
Q10H2 capsules (Q10H2, rapeseed oil, diglyceryl monooleate, bee wax, lecithin) 
were obtained from KANEKA Corporation, Japan. Capsule stabilization was 
ensured by a method disclosed in patent applications (WO 03/06408, WO 
03/06409, WO 03/06410, WO 03/06411, WO 03/06412, WO 03/08363 and WO 
03/32967). 
 
Subjects and study design 
53 healthy male volunteers received 150 mg Q10H2 daily in form of three softgel 
capsules with each principal meal (a´ 50 mg) for 14 days. Fasting blood samples 
(54 ml each) were taken before (T0) and after (T14) supplementation with Q10H2 
from all study participants as well as 4 weeks after study completion (T42, washout 
period) from 9 subjects, respectively. The study design is a simple one-group pre-
post analysis. Based on clinical laboratory tests, all study participants fulfilled the 
following inclusion criteria: 1) no history of gastrointestinal, hepatic, cardiovascular 
or renal disease; 2) no supplemental vitamin use for > 2 weeks before the start of 
the study; 3) non- or occasional smoking (< 3 cigarettes/d); and 4) perpetuation of 
usual nutrition habits. Three males were dropped out for their elevated TNFα or 
CRP levels, three dropped out from the study for personal reasons and one person 
had invalid Q10H2 plasma values after supplementation. The study was approved 
by the ethics committee of the Medical Faculty of Kiel University, Germany, and 
was conformed to Helsinki Declaration. All volunteers gave written informed 
consent.  
 
Plasma CoQ10 content 
HPLC-analysis 
Analysis was based on the method of high-pressure liquid chromatography (HPLC) 
with electrochemical detection and internal standardisation using ubihydroquinone-
9 and ubiquinone-9 as standards and is described elsewhere [30]. In brief, as 
internal standard 15 pmol of ubihydroquinone-9 in 50 µl ethanol were added to 100 
µl plasma sample. Subsequently, the sample was mixed for 1 minute, and the 
suspension was immediately extracted with 500 µl hexane after mixing for further 2 
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minutes. After centrifugation (1000 x g, 5 minutes, 4° C), 300 µl of the supernatant 
was transferred to a separate tube and dried under a stream of argon. Finally, the 
dried residue was redissolved in 40 µ ethanol and injected into the HPLC system. 
 
Gene expression 
Monocyte isolation and RNA extraction  
Monocytes were isolated from EDTA-blood samples (36 ml) of volunteers at each 
indicated time point (T0, T14, T42). Monovettes were stored on ice for a maximum of 
1.5 h until isolation of monocytes. CD14-positive cells were isolated by density 
centrifugation with LymphoPrep™ (Fresenius Kabi Norge, Oslo, Norway) and 
successive magnetic antibody cell sorting (MACS) using micro bead-conjugated 
anti-CD14 antibodies (Miltenyi Biotec, Bergisch Gladbach, Germany) as described 
previously [31]. Monocytes were counted and stored at -80°C until all samples of 
the study had been completely collected. Total RNA was extracted with the 
miRNeasy Isolation Kit, including on-column DNA digestion, according to the 
manufacturer´s instructions (Qiagen, Hilden, Germany). RNA concentration was 
determined by using an ultraviolet spectrometer; RNA integrity number was 
measured with a 2100 Bioanalyzer using the RNA 6000 Nano Kit (Agilent 
Technologies, Santa Clara, USA).  
 
Microarray analysis 
Microarray experiments were performed from monocytes of three volunteers at the 
indicated time points (T0, T14), including a total of six human genome U133 Plus 
2.0 GeneChip® microarrays. Sample selection from volunteers for microarray 
analysis was based on quality and quantity of isolated RNA. RNA integrity, 
indicated as RNA integrity number (RIN), was in a range between 7.5 and 9.2. For 
generation of biotin-labeled cRNA (MessageAmp™ II-Biotin Enhanced Kit, 
Ambion/Applied Biosystems, Darmstadt, Germany), 2 µg total RNA were used for 
each array. Poly-A RNA controls were applied according to the manufacturer´s 
instructions (GeneChip® Eukaryotic Poly A-RNA Control Kit). Using a hybridization 
oven 640, each GeneChip® array was hybridized for 16 h at 45°C with 15 µg 
fragmented, biotin-labeled cRNA, including hybridization controls (GeneChip® 
Eukaryotic Hybridization Control Kit). Subsequently thereafter, arrays were washed 
and stained using Fluidics Station 450. Hybridization, washing and staining 
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solutions were obtained from analogous GeneChip® kits. After hybridization and 
washing procedures, microarrays were scanned with the GeneChip® scanner 3000, 
using GCOS software. If not stated otherwise, all kits and equipment were 
purchased from Affymetrix (High Wycombe, United Kingdom). Fluorescence data 
were obtained in CEL file format. Quality control and normalization procedure of 
the files was performed with R software 2.7.1 and BioConductor 2.0.1 provided by 
the MADMAX database (https://madmax.bioinformatics.nl). Data were normalized 
with the GC-RMA algorithm.  
Initially, only probe sets were selected having the same direction of expression 
changes in all three subjects at each time point, respectively. Secondly, only probe 
sets displaying the highest fold-change values at T14 when compared to T0 (“Top 
50” for up- and down-regulated, respectively, p < 0.05) were chosen. Based on 
gene ontology (GO) terms (http://amigo.geneontology.org), transcripts related to 
inflammation/immune response and/or apoptosis were selected. The complete 
microarray data sets and information about study design and methodology will be 
subsequently submitted to Minimal Information about Microarray Experiments 
(MIAME) at NCBI Gene expression omnibus (GEO) in an applicable format [32].  
 
Quantitative real-time PCR  
SYBR® Green 
Primer sequences for real-time quantitative RT-PCR (qRT-PCR) experiments were 
designed with Primer Express® Software 3.0 (Applied Biosystems, Darmstadt, 
Germany). Primer pairs (Table 1) were obtained from MWG Biotech AG 
(Ebersberg, Germany). cDNA synthesis was initially carried out with the reverse 
transcriptase core kit (Eurogentec, Köln, Germany) on a thermocycler (Biometra, 
Göttingen, Germany). qRT-PCR amplification was performed with the Power 
SYBR® Green PCR Master Mix (Applied Biosystems, Darmstadt, Germany) on an 
Applied Biosystem 7300 qRT-PCR system. Ct-values of target genes were related 
to those of the corresponding housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). 
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TaqMan® 
The TaqMan® MicroRNA Assay (hsa-mir-21) and endogenous control (RNU48) 
were obtained from Applied Biosystems (Darmstadt, Germany). miRNA 
quantification was carried out as two-step RT-PCR. Reverse transcription was 
performed on a thermocycler (Biometra, Goettingen, Germany) with specific 
miRNA primers supplied by the TaqMan® MicroRNA and endogenous control 
assays as well as reagents from the TaqMan® MicroRNA Reverse Transcription Kit. 
During the PCR step, PCR products were amplified from cDNA samples using the 
TaqMan® MicroRNA Assay together with the TaqMan® Universal PCR Master Mix 
(Applied Biosystems). qRT-PCR reactions were performed on an Applied 
Biosystems 7300 Real-Time PCR System. Target sequences were as follows: hsa-
miR-21, UAGCUUAUCAGACUGAUGUUGA; 
RNU48, GAUGACCCCAGGUAACUCUGAGUGUGUCGCUGAUGCCAUCACCGC
AGCGCUCUGACC. 
 
In silico analysis 
For analysis of common pathways between regulated genes, Genomatix Software 
2009 (www.genomatix.de) was used. Probe set IDs of the selected genes were 
uploaded to BibliospherePathwayEdition (BSPE) software. This text mining tool 
identifies putative functional connections of genes based on co-citations with 
transcription factors and other genes in the network from NCBI pubmed [33]. The 
co-citation filter “signal transduction associations” (level ST) was applied. 
 
Secretion levels of pro-inflammatory molecules in native serum and ex vivo 
stimulated whole blood samples  
Ex vivo whole blood stimulation 
Venous blood from study participants was diluted 1:5 with cell culture medium 
(RPMI 1640, Invitrogen, Karlsruhe, Germany) and plated in 24-well format. 
Subsequently after one hour, blood samples were stimulated with LPS (Salmonella 
enteriditis, 20 ng/ml). Unstimulated (-LPS) samples served as controls. Plates were 
further incubated for 6 h at 37 °C in humidified atmosphere. Subsequently 
thereafter, plates were centrifuged and supernatants were removed. Samples were 
stored at -80°C until further analysis.  
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ELISA 
Supernatants of native and/or ex vivo stimulated whole blood samples were 
measured with commercially available ELISA kits for TNFα, MCP-1 (R&D Systems, 
Minneapolis, MN), oxLDL (KAMIYA Biomedical Company, Seattle, USA), CXCL2 
(Promocell, Heidelberg, Germany) and ADMA (DLD Diagnostika, Hamburg, 
Germany). Optical density was read on a microplate reader (Spectramax® 190, 
Molecular Devices).  
 
Comparison of individual mRNA and protein levels  
Relative mRNA levels (qRT-PCR data) for TNFα and CXCL2 from T14 monocyte 
samples were correlated to the respective native serum protein levels of study 
subjects (n = 9). Methods of mRNA (qRT-PCR) and protein (ELISA) quantification 
were already described before.  
 
Determination of LDL cholesterol   
1H NMR analysis 
For analysis of LDL cholesterol levels in serum samples of study subjects, 1H NMR 
spectroscopy was carried out on a Bruker AVANCE II spectrometer operating at 
600 MHz 1H resonance frequency. As NMR-probe a TXI-probe was used and the 
samples were run in 5 mm NMR-tubes with a total of 400 µl.  For serum samples, 
190 µl aliquots of neat serum and 190 µl of PBS were transferred into the NMR 
tube and 20 µl standard solution (deuterium oxide with Sodium 4,4-dimethyl-4-
silapentane-1-sulfonate) were added. 1H NMR spectra were acquired immediately 
after preparation of each individual sample. All spectra were recorded at 37 °C. 1H 
NMR spectra were measured over a spectral width of 12019 Hz which resulted in 
an acquisition time of 2 s. Plasma samples were analyzed using the one-
dimensional nuclear Overhauser and Exchange Spectroscopy (1D NOESY) and 
one-dimensional Carr-Purcell-Meiboom-Gill (1D CPMG) sequence. Data analysis 
was performed using principal component analysis (PCA).   
 
Determination of blood parameters 
Immediately after blood withdrawal, values of haematological variables (leukocytes, 
erythrocytes, reticulocytes, haemoglobin, haematocrit, mean corpuscular volume, 
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mean corpuscular haemoglobin and mean corpuscular haemoglobin concentration) 
were determined by using a haematology autoanalyzer (Sysmex K-1000).  
 
Statistical analysis 
To determine anti-inflammatory and anti-apoptotic effects of Q10H2 
supplementation both on gene expression and protein levels, power calculation 
was involved. Based on power analysis including F-value [95 % power, p < 0.05] of 
12.99, a standard deviation of TNFα levels of σ = 0.7 and literature-based 
differences in TNFα levels between controls and treatment groups of d = 0.5, the 
minimum number of study subjects was determined as 51. Thus, 53 study subjects 
were finally included in the study. Statistics were calculated with SPSS 11.5 
software (SPSS GmbH Software, München, Germany), Microsoft Excel 2003 and 
GraphPad Prism 4.0. Before statistical analysis, normal distribution of the 
parameters was tested. Results were analyzed by a two-sided, paired Students t-
test if not stated otherwise. Levels of statistical significance were set at p <
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Results 
Q10H2 supplementation induces significant increases of total CoQ10 plasma 
levels and its antioxidant redox state  
CoQ10 mediates anti-inflammatory and anti-apoptotic effects in vitro [9-16]. These 
effects were thought to be mediated by the reduced form of CoQ10 (Q10H2). To 
study these effects in humans, 53 healthy male volunteers were supplemented with 
150 mg/d Q10H2 for 2 weeks. Fasting blood samples were taken before (T0) and 
after (T14) supplementation with Q10H2. As shown in table 2, basic characteristics 
(e.g. BMI, fasting glucose, creatinine, blood pressure) of the study subjects were in 
accordance with the inclusion criteria of the study and show values within the 
physiological range for healthy men. Because previous studies with CoQ10 
indicated effects on markers of endothelial dysfunction [34,35], blood pressure and 
asymmetric dimethylarginine (ADMA) was additionally determined. We found no 
effect of CoQ10 on these parameters (Table 2).  
 
Q10H2 plasma concentrations above baseline levels were an essential precondition 
for the study. According to this, cholesterol-related plasma CoQ10 levels (µmol/mol) 
increased significantly from 229.24 ± 61.34 to 1109.75 ± 343.76 (p < 0.0001) for T0 
and T14, respectively (Figure 1A). Four weeks after study completion (T42, washout 
period, n = 9), plasma levels returned to baseline levels of 236.33 ± 77.01 
µmol/mol. Additionally, Q10H2 supplementation reduced plasma levels of the 
oxidized form of CoQ10 (Q10) significantly from 7.47 ± 0.97 % at T0 to 5.95 ± 0.91 % 
at T14 (p < 0.0001) (Figure 1B). However, 4 weeks after washout period, the redox 
state returned nearly to pre-treatment levels with 6.97 ± 0.82 % in the oxidized form 
(p = 0.024). Thus, we were able to increase CoQ10 levels about 4.8-fold in Q10H2-
supplemented persons, with significant lower amounts of the oxidized form. These 
effects were abolished after 4-week washout period.  
 
Identification of 7 Q10H2-sensitive genes involved in inflammatory and 
apoptotic processes 
For the identification of Q10H2-sensitive genes, mRNA steady state levels of 25.044 
probe sets in monocyte samples of 3 study subjects before (T0) and after (T14) 
Q10H2 supplementation were determined. Based on selection criteria (see Materials 
and Methods) for the microarray experiment, 272 unique probe sets were 
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significantly regulated (fold change > 1.5, p < 0.05) through Q10H2 treatment. Out of 
these, 56 probe sets were up-regulated and 216 probe sets were down-regulated 
with a fold change ranging from 1.52 to 2.85 and -1.51 to -27.30, respectively 
(Tables 3 and 4). Based on gene ontology (GO) terms, nine transcripts (TNFα, 
CXCL2, IL8, CCL3, GIMAP7, NR4A2, BRE, PMAIP1 and miR21) related to 
inflammatory/immune response and/or apoptotic processes were selected for 
further analysis. In order to identify common pathways of these genes, we 
performed a text mining approach. As shown in figure 3, the Q10H2-sensitive genes 
seem to play a role in peroxisome proliferator-activated receptor (PPAR)-signalling 
and cell proliferation (TP53) pathways, finally connected by NFκB. 
 
Control and extended analysis confirms microarray data 
As shown in table 5, technical verification supported the results of the microarray 
data (Table 5). Biological verification and an extended analysis of these data was 
performed in six additional samples from volunteers as well as in monocyte 
samples from 4 weeks after discontinuation of Q10H2-supplementation (“washout”). 
With exception for the CXCL2 gene, expression levels of TNFα, CCL3, GIMAP7, 
NR4A2, BRE and PMAIP1 returned nearly to pre-treatment levels after 4 weeks of 
study completion. In more detail, the pro-inflammatory Tumour necrosis factor 
alpha (TNFα) gene shows 61.1 ± 5.3 % reduced expression levels at T14 (p = 
0.0021) (Figure 2A). This effect was nearly declined after an one-month washout 
period (T42), even though to a reduced extent (73 ± 14.1 % of T0, p = 0.025). The 
chemokine (C-X-C motif) ligand 2 gene (CXCL2, macrophage inflammatory 
protein-2-alpha, MIP-2α) and chemokine (C-C motif) ligand 3 (CCL3, MIP-1α) were 
also shown to be down-regulated about 72 ± 9.8 % (p < 0.0001) and 41.7 ± 16.1 % 
(p = 0.0171) at T14, respectively (Figure 2B and 2C). In comparison to the other 
Q10H2-sensitive genes, the Q10H2-mediated effects on CXCL2 and CCL3 
expression seem to be more persistent. At washout period, only 44.8 ± 11.8 % and 
66.4 ±14.5 % of the baseline levels were achieved (Figure 2B and 2C). Two further 
genes that were significantly down-regulated at T14 are the nuclear receptor 
subfamily 4, group A, member 2 (NR4A2 or NURR1) gene and the brain and 
reproductive organ expressed (BRE) gene, namely to 37.3 ± 9.9 % (p = 0.0285) 
and 64.9 ± 9.7 % (p = 0.0009), respectively (Figure 2D and 2F). After washout 
period, the effects on NR4A2 and BRE gene expression returned to 67.1 ± 10 % 
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and 83.5 ± 8.6 % of the baseline (T0) levels (Figure 2D and 2F). Another gene that 
was significantly down-regulated to 52.6 ± 9.7 % (p = 0.0019) in monocytes of 
Q10H2-supplemented persons was phorbol-12-myristate-13-acetate-induced protein 
1 (PMAIP1) (Figure 2G). After washout period, the effects returned to 97.7 ± 
23.6 % of the baseline (T0) level. Only one gene, the GTPase, IMAP family 
member 7 (GIMAP7), was significantly up-regulated about 44.7 % at T14 (p = 
0.032), but returned also nearly to baseline levels (about 86.7 ± 10.3 % of T0) after 
washout period (Figure 2E).  
 
Q10H2 supplementation shows significant anti-inflammatory effects on the 
transcriptional but not on the protein level  
To confirm the observed anti-inflammatory effects of CoQ10 on gene expression at 
the protein level, relevant inflammatory markers were examined in serum samples. 
However, no significant effects of Q10H2 supplementation were observed for 
Tumour necrosis factor alpha (TNFα), Monocyte chemotactic protein-1 (MCP-1), 
chemokine (C-X-C motif) ligand 2 (CXCL2) and C-reactive protein (CRP) (Table 7). 
Of note, comparison between mRNA and protein levels of the inflammatory 
mediators TNFα and CXCL2 revealed no correlation (Figure 4). Additionally, we 
analysed anti-inflammatory effects of Q10H2 at the protein level with an ex vivo 
approach. Before and after CoQ10 supplementation whole blood samples were 
stimulated with LPS and the resulting secretion levels of TNFα and MCP-1 were 
determined. As shown in table 6, mean levels of TNFα and MCP-1 increased 
significantly in LPS stimulated whole blood samples when compared to controls (-
LPS). TNFα responses increased 26.42- and 29.67-fold (p < 0.0001) at T0 and T14, 
respectively. MCP-1 levels increased 1.76- and 1.70-fold after LPS stimulation (p < 
0.0001). However, the stimulation values showed no differences between T0 and 
T14. Taken together, Q10H2 supplementation mediates anti-inflammatory effects on 
the transcriptional but not on the protein level. 
 
Q10H2 supplementation induces a significant reduction of serum LDL 
cholesterol levels  
With respect to the results from our in silico analysis (Figure 3), Q10H2-mediated 
effects on peroxisome proliferator-activated receptors (PPAR) signalling pathways 
were hypothesized. Because PPARs are known key players in lipid and cholesterol 
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metabolism [36], effects on serum lipid parameters were additionally analyzed. As 
determined by routine laboratory tests, a significant reduction of low-density 
lipoprotein (LDL) cholesterol levels has been found in serum samples of study 
subjects (from 95.51 ± 28.89 mg/dl to 90.60 ± 27.21 mg/dl, p = 0.022) (Table 8). No 
significant effects were found for other lipid parameters including total cholesterol, 
high-density lipoprotein (HDL) cholesterol, oxidized LDL (oxLDL) and triglycerides 
(TG) (Table 8). The reducing effect on LDL cholesterol levels was additionally 
shown by 1H NMR analysis (from 75.0 to 65.5 mg/dl) with no effects on LDL 
particle size. The observed effects on total LDL cholesterol levels are mediated 
through significant reductions of three LDL subfractions including B, C and E with 
relative reductions of 33.02 % (p = 0.00002), 14.62 % (p = 0.0098) and 16.52 (p = 
0.008), respectively (Figure 5). In contrast, no Q10H2-mediated alterations were 
found for the LDL subfractions A and D. Taken together, Q10H2 supplementation 
mediates distinct reducing effects on LDL cholesterol levels. 
 
Q10H2 supplementation alters haematological parameters in the blood 
Caspases are involved in various cell differentiation processes [37-39]. The 
production and differentiation of red blood cells (erythropoiesis) is related to 
caspase 8 activation [40]. Because we identified the monocyte to macrophage 
differentiation gene (MMD, Table 4) and the caspase 8 and FADD-like apoptosis 
regulator gene (CFLAR, Table 3) as Q10H2-senstive genes in isolated human 
monocytes and liver tissues of SAMP1-mice as well (unpublished results), 
haematological parameters were determined in study subjects before and after 
Q10H2 supplementation. As shown in table 9, parameters of erythropoiesis [41] 
were significantly changed in the blood. The number of erythrocyte and 
haematocrit values decreased significantly from 4.95 ± 0.29 to 4.89 ± 0.31 (p = 
0.02) and 44.48 ± 2.36 to 43.78 ± 2.40 (p = 0.01), respectively, for T0 and T14. 
Mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin 
concentration (MCHC) and reticulocyte count increased significantly from 30.62 ± 
1.12 to 30.82 ± 1.17 (p = 0.02), 34.09 ± 0.53 to 34.33 ± 0.53 (p = 0.02) and 10.94 ± 
3.03 to 12.09 ± 2.46 (p = 0.0006), respectively, at T0 and T14. No significant effects 
were found for leukocyte count and haemoglobin concentration (Table 9). In 
conclusion, Q10H2-supplementation affects parameters related to erythroid 
differentiation processes. 
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Discussion  
 
Assumption 1 
Q10H2 modulates the expression of inflammatory genes at mRNA level but not 
at protein level. 
In the present study, 53 male volunteers were supplemented with the reduced form 
of CoQ10 (Q10H2) for 2 weeks. To identify Q10H2-sensitive genes related to 
inflammatory and apoptotic processes, gene expression profiles in monocytic cells 
of study subjects were analysed. Monocytes have been described as a reliable 
model to study anti-inflammatory and anti-apoptotic effects in vivo [26,27,42]. TNFα, 
CXCL2, CCL3, GIMAP7, NR4A2, BRE and PMAIP1 were assigned as Q10H2-
sensitive genes involved in inflammatory and apoptotic processes. GIMAP7 
belongs to the group of GTPases which are exclusively expressed in cells of the 
immune system including macrophages and peripheral blood leukocytes [43,44]. 
GTPases are thought to regulate a variety of different processes in cells including 
their action as tumor suppressors [43]. TNFα, CXCL2 and CCL3 are described as 
key players in the maintenance of inflammatory responses in monocytes and 
macrophages [45-50]. NR4A2 has been shown to modulate apoptotic processes 
[51,52] but to be also involved in inflammatory cascades [53,54]. BRE was 
reported to play a significant key role in proliferative responses [55], endocrine and 
immune functions [56] as well as apoptosis [57]. PMAIP1 has been shown to be 
involved in apoptotic processes [58,59].  
 
For verification of Q10H2-mediated transcriptional effects on the protein level, 
concentrations of relevant inflammatory mediators (TNFα, CXCL2, MCP-1, CRP) 
were additionally determined in serum samples of study subjects. However, no 
significant differences were observed. Comparisons between individual mRNA and 
protein levels of the pro-inflammatory mediators TNFα and CXCL2 – each playing 
a distinct role in monocyte/macrophage activation processes [60-63] – revealed no 
significant correlation as well. Because triggering of monocytes with LPS leads to 
an activation of the transcription factor NFκB and, hence, the release of pro-
inflammatory mediators [64,65], this ex vivo approach was additionally applied to 
determine putative anti-inflammatory effects of Q10H2 on the protein level. Q10H2-
mediated effects on the reduction of several pro-inflammatory molecules have 
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been already described in vitro [9-11]. With regard to our ex vivo approach, no 
Q10H2-mediated effect on LPS-induced secretion levels of TNFα and MCP-1 was 
found. One explanation for the observed discrepancies regarding the Q10H2 effects 
on inflammation at the protein level in in vitro and in vivo studies could be the 
heterogeneity of blood plasma and serum matrices when compared to isolated cell 
culture systems. Q10H2-independent posttranscriptional (e.g. micro RNAs) [66] and 
posttranslational mechanisms [67] leading to a reduced activity or stability of the 
synthesized mRNAs and proteins may account for different effects of Q10H2 on 
mRNA and protein level. In view of the in vivo and ex vivo data, the Q10H2-
mediated effects on inflammation are considered to occur mainly at the 
transcriptional level. 
 
Assumption 2 
Q10H2 affects cell differentiation through PPARα signalling cascade. 
Putative common pathways between the Q10H2-regulated genes were identified by 
text mining analysis. Based on co-citations with transcription factors and other 
genes in the network, 6 genes (TNFα, CCL3, CXCL2, NR4A2, BRE and PMAIP1) 
were functionally connected with each other. The associated genes were identified 
to play a role in PPAR-signalling and cell proliferation (TP53) pathways, centrally 
connected by NFκB. Effects of Q10H2 supplementation on PPARα signalling 
pathways were already found in liver tissues of SAMP1 mice [6]. In this context, the 
identified Q10H2-sensitive genes showed a partial involvement in cell differentiation 
processes. As cell differentiation plays a crucial role in human monocytes [68,69], 
putative effects of Q10H2 supplementation on genes involved in 
monocyte/macrophage differentiation processes were additionally determined. In 
agreement to the consistent results of microarray [6] and qRT-PCR results 
(unpublished data) from liver tissue of 14-months supplemented (14 M) SAMP1 
mice, the human monocyte to macrophage differentiation gene (MMD) was also 
significantly down-regulated (-1.73, p = 0.04) in monocytes of Q10H2-supplemented 
subjects (Table 4). A modulatory role of Q10H2 in PPARα mediated differentiation 
processes is additionally indicated by the down-regulation of the PMAIP1 (Noxa) 
gene, which is also involved in cell differentiation cascades by induction of 
apoptosis signalling pathways [59].  
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With regard to previous studies [12-16] and our present data on gene expression 
(Table 5), anti-apoptotic effects of Q10H2 are suggested. Because the monocyte to 
macrophage differentiation process is linked to apoptosis [68], caspases are 
thought to be putative upstream regulators in the modulation of the monocyte to 
macrophage differentiation gene (MMD). Moreover, although in most cases 
caspase activation is linked to apoptosis, recent evidence indicates nonapoptotic 
functions of caspase 8 [70-72]. As caspase 8 activation has been shown to down-
regulate the transcription factor NFκB, which in turn is hypothesized to favour the 
macrophage differentiation process [73], caspase 8 and FADD-like apoptosis 
regulator gene (CFLAR) was ascribed as further putative Q10H2 target gene. In fact, 
microarray analysis of monoycte samples revealed a 2.13-fold increase of CFLAR 
gene expression (p = 0.02) in monocytes of Q10H2 supplemented volunteers (Table 
3). Moreover, a significant induction of CFLAR gene expression (1.77-fold, p = 
0.02) was also found in liver tissues of SAMP1 mice supplemented with Q10H2 for 
14 months (unpublished results) [6]. Taken together, Q10H2 may inhibit the 
monocyte to macrophage differentiation process via modulation of MMD and 
CFLAR gene expression.   
 
Because processes such as liver hematopoietic stem cell proliferation and red 
blood cell differentiation (erythropoiesis) are also related to caspase 8-dependent 
mechanisms [40,72], effects on haematological parameters were determined. 
Significant effects of Q10H2 supplementation have been found for parameters 
related to erythrocyte differentiation and proliferation processes (erythropoiesis) 
[41]. Thus, the number of mature erythrocyte and haematocrit values decreased 
significantly in blood samples of study subjects after Q10H2 supplementation. In 
contrast, values of mean corpuscular haemoglobin (MCH), mean corpuscular 
haemoglobin concentration (MCHC) and reticulocyte count were significantly 
increased. Reticulocytes are described as immature erythrocytic cells in the 
peripheral blood that are in a penultimate phase of maturation [74]. Because the 
number of reticulocytes was significantly increased after Q10H2-supplementation, 
as well as the number of mature erythrocytes reduced, Q10H2-mediated effects on 
differentiation and/or proliferation processes related to erythropoiesis were 
hypothesized. Taken together, gene expression data from mice and humans as 
  17 
well as cellular parameters from the human study indicate an involvement of Q10H2 
in cell differentiation processes through PPARα signalling cascade.  
 
Assumption 3 
Q10H2 reduces LDL cholesterol.  
Because PPARs are known key players in lipid and cholesterol metabolism 
[36,75,76], effects on serum lipid parameters were additionally determined. 
Significant reducing effects were found for LDL cholesterol in serum samples of 
study subjects after Q10H2 supplementation. More recently, Q10H2-mediated effects 
on PPARα gene expression patterns were discussed in liver tissues of SAMP1 
mice [6]. In this context, several genes related to lipid and cholesterol metabolism 
as well as cell differentiation processes were identified to be regulated in liver 
tissues of mice by Q10H2-treatment. Because Q10H2 is primarily incorporated in LDL 
particles during its transport in the blood [77], it is able to prevent LDL oxidation 
processes in vivo and in vitro [78-80]. This in turn may inhibit the oxLDL-mediated 
liver X receptor (LXR) activation [81,82] and subsequent up-regulation of ABC 
transporter genes, finally leading to a decreased cellular cholesterol efflux as well 
[83-85]. In general, the physiological relevance of the observed lowering effect of 
Q10H2 supplementation on LDL cholesterol levels in our human study (12.7 % from 
NMR-based data) is comparable to these described for plant sterols in different 
cohorts. Plant sterols, which are structurally related to cholesterol, mediate distinct 
lowering effects on LDL plasma levels [83]. It has been shown that an usual daily 
intake of 2 – 2.5 g plant sterols or stanols results in an average reduction of LDL 
cholesterol levels of up to 14 % [86,87].  
 
Assumption 4 
Q10H2 affects NFκB/PPAR-mediated signalling pathways which connect cell 
differentiation and inflammatory processes.  
Although in most cases caspase activation is linked to apoptosis, recent evidence 
indicates nonapoptotic functions of caspase 8 and/or FADD-like apoptosis 
regulator gene [59,70-72,88]. This might also explain the results from previous in 
vitro experiments [12-16] as well as from our present gene expression data in 
human monocytes where anti-apoptotic effects of CoQ10 are evident. Furthermore, 
caspase 8 has been shown to prevent the activation of the nuclear transcription 
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factor NFκB in monocytes [73] and thus, an undergoing differentiation process into 
macrophages. In addition, PPARs have been described to interact with the nuclear 
transcription factor NFκB [89]. PPARα activators can inhibit the translocation 
process of NFκB into the nucleus [90,91], thereby preventing the expression of pro-
inflammatory genes. Moreover, mechanisms of transrepression could also account 
for the Q10H2-mediated effects on gene expression, which are due to protein-
protein interactions between PPARα and the promoter-bound transcription factor 
NFκB [89]. However, independently of the molecular mechanisms underlying NFκB 
inhibition, PPARs are known key regulators of inflammatory processes and lipid 
homeostasis [92]. PPARα has been shown to be already expressed in 
undifferentiated monocytes, whereas PPARγ expression is initially induced upon 
differentiation into macrophages [76]. Additionally, PPARα activators have been 
described to prevent differentiation processes in human monocytes [76], whereas 
PPARγ seems to be absent in these cells [93]. In general, a distinct role of Q10H2 in 
PPARα mediated cell differentiation processes is suggested by the down-
regulation of the PMAIP1 and MMD gene in human monocytes, probably mediated 
by caspase 8 and/or PPARα mediated inhibition of NFκB.  
 
Conclusion 
In conclusion, Q10H2-supplementation in humans modulates the expression of 
genes involved in inflammation at mRNA level but not at protein level, reduces LDL 
cholesterol and affects cell differentiation processes. These effects are 
hypothesized to be mediated by the antioxidant properties of Q10H2 through NFκB 
and PPARα dependent gene expression. 
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Figure legends 
 
Figure 1 
Analysis of total CoQ10 levels and its redox state in plasma samples of study 
subjects before (T0) and after supplementation with Q10H2 (T14) as well as 
after 4-wk washout period (T42) 
Data present effects on total CoQ10 levels (A), and its redox state (B) before (T0) 
and after Q10H2 supplementation (T14) as well as after 4-week washout period (T42). 
Data are calculated from means (± SEM) of 53 measurements for T0 and T14, as 
well as 9 measurements for T42, respectively. 
 
Figure 2  
Expression levels of Q10H2-sensitive genes involved in inflammatory and 
apoptotic processes in human monocytes 
Technical as well as biological verification experiments (qRT-PCR) of monocyte 
samples revealed the expression of 7 Q10H2-sensitive genes related to 
inflammatory and apoptotic processes: TNFα (A), CXCL2 (B), CCL3 (C), NR4A2 
(D), GIMAP7 (E), BRE (F) and PMAIP1 (G). Data are means (± SEM) of samples 
from 9 volunteers, respectively. *p < 0.05, **p < 0.01, ***p < 0.001 
 
Figure 3 
Bibliosphere network of genes regulated in monocytes of Q10H2 
supplemented volunteers 
Based on co-citations with transcription factors and other genes in the network (ST 
level), the identified Q10H2-sensitive genes were connected with each other by 
BiblioSpherePathwayEdition Software. According to this, these genes seem to play 
a role in PPAR-signalling and cell proliferation (TP53) pathways, finally connected 
by NFκB. 
 
Figure 4 
Correlation between individual mRNA and protein levels of TNFα and CXCL2 
after Q10H2 supplementation  
Relative mRNA levels for TNFα and CXCL2 were correlated to respective serum 
protein levels of study subjects (n = 9) after Q10H2 supplementation (T14).  
No correlation was found between these parameters.
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Figure 5 
Effects of Q10H2 supplementation on LDL subfractions in serum samples of 
study subjects 
Based on NMR analysis, effects of Q10H2 supplementation on concentrations 
(nmol/l) of LDL subfractions (A-E) were analysed in serum samples of study 
subjects (n = 53). Significant effects have been found for the LDL subfractions B, C 
and E with relative reductions of 33.02, 14.62 and 16.52 %, respectively.  
**p < 0.01; ***p < 0.001 
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Tables  
Table 1 Nucleotide sequences of primer pairs used for the real-time qRT-PCR 
experiments 
Gene Primer sequence forward (5´-3´) Primer sequence reverse (5´-3´) 
NR4A2 CCG CCA GCA ATA ATT GAC AA TGC TTG GGA GGA GGT CTT AGA A 
GIMAP7   GCT CCC TGA GGA TCG TTC TG GGT GTT CGC TGT TGC ACT TTT 
IL8 CAC CGG AAG GAA CCA TCT CA AGA GCC ACG GCC AGC TT 
KLF6 TCC TGT AAG AAG CGG CAT AGC GAG TCC AGG GTC ACC CAC AT 
PMAIP1 AGC TGG AAG TCG AGT GTG CTA CT CTG CCG GAA GTT CAG TTT GTC 
TAGAP GAG TTA TGC TGT TTC TCC CAT TCT TTA TGG AGG GTC TCT AGC CAG AGT T 
BRE GGA GGC AGC ATT TGC CAA T GGC TGG CCA CCT CTC AAG A 
CXCL2 GAT GCT GAA AAA TGG CAA ATC C CAG GAA CAG CCA CCA ATA AGC 
CCL3 CCG TCA CCT GCT CAG AAT CAT GGT GCA GAG GAG GAC AGC AA 
TNFα GCA GGT CTA CTT TGG GAT CAT TG GCG TTT GGG AAG GTT GGA 
GAPDH
 
ATG GAA ATC CCA TCA TCT T CGC CCC ACT TGA TTT TGG 
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Table 2 Characteristics of study subjects before (T0) and after 2-wk 
supplementation period (T14) with Q10H2 (n = 53) 
Parameters T0 T14 
Age (years) 30.13 ± 6.71 30.13 ± 6.71 
Weight (kg) 79.11 ± 10.17 79.18 ± 10.01 
Height (m) 1.81 ± 0.06 1.81 ± 0.06 
BMI (kg/m2) 24.12 ± 2.50 24.14 ± 2.44 
Glucose 86.47 ± 10.68 84.26 ± 10.10 
Creatinine 1.05 ± 0.10 1.07 ± 0.12 
GOT1 30.09 ± 8.67 33.06 ± 35.95 
GPT2 37.79 ± 14.73 37.26 ± 16.52 
γ-GT3 20.49 ± 10.36 17.79 ± 7.68*** 
Blood pressure (mm Hg)   
systolic  126.79 ± 12.00 126.11 ± 12.29 
diastolic  82.74 ± 9.31 81.79 ± 8.46 
ADMA (µmol/l) 0.98 ± 0.27 1.11 ± 0.50 
Data are described as means + SD 
***
 T0 vs. T14, p < 0.001  
1Glutamate-Oxalacetate-Transferase (ASAT, Aspartat-Aminotransferase) 
2Glutamat-Pyruvat-Transaminase (ALAT, Alanin-Aminotransferase) 
3Gamma-Glutamyl-Transferase 
 
 
 
 
 
  31 
Table 3 Q10H2 up-regulated genes (FC > 1.5, p < 0.05)  
Affymetrix 
Probe Set ID 
Gene symbol Gene name Mean fluorescence data ± SD (n = 3) FC 
   
T0  T14  
   
Mean ± SD  Mean ± SD  
206765_at KCNJ2 potassium inwardly-rectifying channel, subfamily J, member 2 36.10 21.24  102.99 19.49 2.85 
228071_at GIMAP7 GTPase, IMAP family member 7 1468.59 1013.58  3738.86 176.80 2.55 
224917_at MIRN21 microRNA 21 630.29 229.14  1540.31 285.74 2.44 
229543_at --- --- 180.90 83.70  439.44 24.44 2.43 
228362_s_at RP1-93H18.5 Hypothetical protein LOC441168 101.95 63.32  241.44 17.00 2.37 
235837_at --- Transcribed locus, weakly similar to NP_775735.1 l(3)mbt-like 
4 [Homo sapiens] 
37.23 17.81  82.71 4.73 2.22 
239629_at CFLAR CASP8 and FADD-like apoptosis regulator 210.89 77.04  448.26 82.51 2.13 
206584_at LY96 lymphocyte antigen 96 778.64 445.09  1633.35 38.54 2.10 
1563357_at --- MRNA; cDNA DKFZp564C203 (from clone DKFZp564C203) 123.81 57.72  251.93 50.51 2.03 
214149_s_at ATP6V0E ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e 178.41 69.51  357.57 77.63 2.00 
236492_at PPP2R2A protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 
52), alpha isoform 
106.20 36.21  210.57 49.63 1.98 
229391_s_at RP1-93H18.5 hypothetical protein LOC441168 933.38 506.28  1849.49 158.35 1.98 
230466_s_at RASSF3 Ras association (RalGDS/AF-6) domain family 3 592.99 311.33  1152.57 157.69 1.94 
1569129_s_at --- Homo sapiens, clone IMAGE:4695648, mRNA 129.13 56.43  248.60 28.00 1.93 
225580_at MRPL50 mitochondrial ribosomal protein L50 60.68 23.54  115.14 12.34 1.90 
229970_at --- --- 11.38 1.20  21.53 2.73 1.89 
231697_s_at TMEM49 Transmembrane protein 49 98.53 36.39  186.01 14.77 1.89 
230559_x_at FGD4 FYVE, RhoGEF and PH domain containing 4 118.96 16.08  221.95 19.05 1.87 
241617_x_at --- --- 33.26 5.03  61.93 10.23 1.86 
227284_at ZNF766 zinc finger protein 766 61.83 15.84  113.61 10.72 1.84 
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Affymetrix 
Probe Set ID 
Gene symbol Gene name Mean fluorescence data ± SD (n = 3) FC 
   
T0  T14  
   
Mean ± SD  Mean ± SD  
232034_at LOC203274 hypothetical protein LOC203274 99.20 38.23  180.30 21.02 1.82 
218732_at PTRH2 peptidyl-tRNA hydrolase 2 169.90 78.36  308.20 23.61 1.81 
217144_at UBB /// 
LOC648390 
ubiquitin B /// similar to ubiquitin B precursor 38.91 9.12  69.98 4.76 1.80 
236165_at --- --- 39.95 6.13  71.45 8.15 1.79 
220992_s_at C1orf25 chromosome 1 open reading frame 25 /// chromosome 1 open 
reading frame 25 
67.36 8.50  119.34 14.04 1.77 
204531_s_at BRCA1 breast cancer 1, early onset 24.59 6.70  43.20 5.21 1.76 
1560327_at --- CDNA clone IMAGE:5273088 104.58 30.60  182.30 12.64 1.74 
228964_at PRDM1 PR domain containing 1, with ZNF domain 18.94 5.22  32.72 4.88 1.73 
209007_s_at C1orf63 chromosome 1 open reading frame 63 2693.11 1150.59  4625.48 258.16 1.72 
219146_at C17orf42 chromosome 17 open reading frame 42 61.16 18.97  104.66 0.72 1.71 
240452_at GSPT1 G1 to S phase transition 1 22.12 5.23  37.76 8.03 1.71 
229934_at --- Transcribed locus 263.06 62.99  448.45 66.40 1.70 
229804_x_at CBWD1 /// 
CBWD2 /// 
CBWD3 /// 
CBWD6 
COBW domain containing 1 /// COBW domain containing 2 /// 
COBW domain containing 3 /// COBW domain containing 6 
305.28 41.21  507.59 93.68 1.66 
210528_at MR1 major histocompatibility complex, class I-related 32.26 7.54  53.55 6.34 1.66 
209850_s_at CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 70.68 17.39  116.76 14.78 1.65 
203739_at ZNF217 zinc finger protein 217 764.24 233.92  1256.33 79.59 1.64 
224321_at TMEFF2 transmembrane protein with EGF-like and two follistatin-like 
domains 2 /// transmembrane protein with EGF-like and two 
follistatin-like domains 2 
203.39 37.27  334.07 38.49 1.64 
231252_at FLJ23861 hypothetical protein FLJ23861 14.27 2.31  23.41 4.39 1.64 
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Affymetrix 
Probe Set ID 
Gene symbol Gene name Mean fluorescence data ± SD (n = 3) FC 
   
T0  T14  
   
Mean ± SD  Mean ± SD  
235306_at GIMAP8 GTPase, IMAP family member 8 1826.70 455.55  2986.27 363.18 1.63 
222701_s_at CHCHD7 coiled-coil-helix-coiled-coil-helix domain containing 7 297.13 95.72  485.68 35.06 1.63 
227636_at THAP5 THAP domain containing 5 151.52 49.58  245.00 25.51 1.62 
1561179_s_at AMZ1 archaemetzincin-1 23.00 5.02  36.52 5.36 1.59 
226077_at FLJ31951 hypothetical protein FLJ31951 569.70 180.89  903.10 18.93 1.59 
221634_at RPL23AP7 ribosomal protein L23a pseudogene 7 42.56 6.66  67.33 11.51 1.58 
230259_at C10orf125 chromosome 10 open reading frame 125 108.71 26.40  171.74 28.56 1.58 
206141_at MOCS3 molybdenum cofactor synthesis 3 19.63 5.72  30.92 1.92 1.57 
213233_s_at KLHL9 kelch-like 9 (Drosophila) 116.55 15.77  182.48 20.04 1.57 
223477_s_at FLJ38663 hypothetical protein FLJ38663 22.22 7.29  34.67 1.24 1.56 
228714_at --- CDNA FLJ46701 fis, clone TRACH3014063 14.30 0.77  22.10 1.55 1.55 
1564820_at RAB6A RAB6A, member RAS oncogene family 21.79 4.07  33.53 2.94 1.54 
1564207_at FLJ35390 hypothetical protein FLJ35390 138.82 24.87  213.15 21.19 1.54 
213891_s_at --- CDNA FLJ37747 fis, clone BRHIP2022986 172.43 28.72  264.00 36.52 1.53 
236703_at --- Transcribed locus, strongly similar to NP_036361.1 5'-
nucleotidase, cytosolic II; purine 5' nucleotidase; 5'-
nucleotidase (purine), cytosolic type B; IMP-specific 5'-NT 
[Homo sapiens] 
107.42 11.89  164.45 22.30 1.53 
230852_at STAC3 SH3 and cysteine rich domain 3 54.10 6.09  82.79 8.40 1.53 
1554948_at --- --- 122.16 11.34  186.59 23.81 1.53 
224346_at RNPS1 RNA binding protein S1, serine-rich domain /// RNA binding 
protein S1, serine-rich domain 
73.66 16.02  111.67 6.00 1.52 
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Table 4 Q10H2 down-regulated genes (FC < -1.5, p < 0.05)  
Affymetrix 
Probe set ID 
Gene symbol Gene name Mean fluorescence data ± SD (n = 3) FC 
   
T0  T14  
   
Mean ± SD  Mean ± SD  
211506_s_at IL8 interleukin 8 1525.09 1372.25  55.87 12.92 -27.30 
202859_x_at IL8 interleukin 8 5053.70 4423.82  328.78 176.29 -15.37 
209774_x_at CXCL2 chemokine (C-X-C motif) ligand 2 1149.75 865.42  93.01 29.81 -12.36 
205114_s_at CCL3 /// 
CCL3L1 /// 
CCL3L3 /// 
LOC643930 
chemokine (C-C motif) ligand 3 /// chemokine (C-C motif) 
ligand 3-like 1 /// chemokine (C-C motif) ligand 3-like 3  
4591.46 2758.68  658.29 390.95 -6.97 
204621_s_at NR4A2 nuclear receptor subfamily 4, group A, member 2 664.26 412.31  100.46 37.53 -6.61 
1568768_s_at BRE brain and reproductive organ-expressed (TNFRSF1A 
modulator) 
94.61 8.87  14.32 5.31 -6.61 
1569203_at CXCL2 chemokine (C-X-C motif) ligand 2 95.67 70.08  18.62 5.84 -5.14 
204622_x_at NR4A2 nuclear receptor subfamily 4, group A, member 2 225.64 124.59  47.81 23.25 -4.72 
207113_s_at TNF tumor necrosis factor (TNF superfamily, member 2) 158.26 92.90  36.66 11.52 -4.32 
216248_s_at NR4A2 nuclear receptor subfamily 4, group A, member 2 339.55 175.82  81.18 31.04 -4.18 
239845_at --- Transcribed locus 204.27 36.38  51.10 5.82 -4.00 
215322_at LONRF1 LON peptidase N-terminal domain and ring finger 1 228.80 85.12  67.15 15.69 -3.41 
AFFX-r2-Bs-phe-
5_at 
--- --- 519.41 182.15  156.45 25.67 -3.32 
AFFX-PheX-5_at --- --- 205.75 56.79  62.29 6.86 -3.30 
234050_at TAGAP T-cell activation GTPase activating protein 589.38 87.94  180.95 76.67 -3.26 
AFFX-r2-Bs-thr-
3_s_at 
--- --- 846.31 326.33  267.05 13.67 -3.17 
AFFX-ThrX-3_at --- --- 643.53 255.90  204.79 34.05 -3.14 
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Affymetrix 
Probe set ID 
Gene symbol Gene name Mean fluorescence data ± SD (n = 3) FC 
   
T0  T14  
   
Mean ± SD  Mean ± SD  
239405_at RAB7 RAB7, member RAS oncogene family 34.02 5.70  10.95 1.58 -3.11 
217591_at SKIL SKI-like 406.23 127.63  131.90 3.45 -3.08 
204470_at CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha) 
85.90 24.87  28.07 8.40 -3.06 
AFFX-PheX-M_at --- --- 281.60 50.70  98.82 19.88 -2.85 
202014_at PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit 15A 756.92 300.49  268.40 46.19 -2.82 
1566901_at TGIF TGFB-induced factor (TALE family homeobox) 56.39 3.69  20.25 4.07 -2.78 
242587_at SLC9A9 solute carrier family 9 (sodium/hydrogen exchanger), 
member 9 
31.40 11.26  11.66 1.13 -2.69 
231904_at U2AF1 U2 small nuclear RNA auxiliary factor 1 550.70 188.82  211.10 13.47 -2.61 
1556072_at FLJ40542 hypothetical protein FLJ40542 249.57 43.03  95.92 16.41 -2.60 
AFFX-r2-Bs-lys-5_at --- --- 359.81 9.17  138.98 30.87 -2.59 
1556602_at SLC19A2 Solute carrier family 19 (thiamine transporter), member 2 40.29 3.21  15.57 3.80 -2.59 
AFFX-r2-Bs-phe-
M_at 
--- --- 596.38 129.10  233.22 70.92 -2.56 
AFFX-LysX-M_at --- --- 203.52 10.10  79.88 18.84 -2.55 
1552542_s_at TAGAP T-cell activation GTPase activating protein 300.79 52.43  122.45 55.35 -2.46 
240094_at TXNDC13 Thioredoxin domain containing 13 427.84 138.66  177.58 51.24 -2.41 
221765_at --- --- 43.71 7.44  18.50 1.77 -2.36 
AFFX-LysX-5_at --- --- 244.06 2.50  105.50 29.04 -2.31 
AFFX-r2-Bs-phe-
3_at 
--- --- 486.84 44.95  213.37 35.26 -2.28 
1557459_at SNF1LK2 SNF1-like kinase 2 64.20 16.64  28.32 12.16 -2.27 
239494_at LOC646725 hypothetical protein LOC646725 /// hypothetical protein 102.67 30.34  45.30 10.86 -2.27 
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Affymetrix 
Probe set ID 
Gene symbol Gene name Mean fluorescence data ± SD (n = 3) FC 
   
T0  T14  
   
Mean ± SD  Mean ± SD  
/// 
LOC649431 
LOC649431 
242210_at ZNF24 Zinc finger protein 24 17.48 3.75  7.78 0.22 -2.25 
232392_at SFRS3 Splicing factor, arginine/serine-rich 3 60.67 13.34  27.22 7.54 -2.23 
204285_s_at PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 1270.73 35.11  577.55 106.44 -2.20 
AFFX-PheX-3_at --- --- 308.89 33.47  140.89 20.77 -2.19 
224854_s_at KIAA1458 KIAA1458 31.03 4.26  14.20 3.23 -2.18 
AFFX-r2-Bs-lys-3_at --- --- 393.18 21.67  182.30 42.96 -2.16 
215415_s_at LYST lysosomal trafficking regulator 44.71 10.62  21.49 5.26 -2.08 
217649_at --- Transcribed locus, strongly similar to XP_371170.1 
PREDICTED: similar to Zinc finger protein 216 [Homo 
sapiens] 
200.13 12.39  97.50 14.50 -2.05 
AFFX-r2-Bs-lys-
M_at 
--- --- 399.84 50.81  195.60 49.93 -2.04 
232141_at U2AF1 U2 small nuclear RNA auxiliary factor 1 518.65 64.09  254.12 43.49 -2.04 
210204_s_at CNOT4 CCR4-NOT transcription complex, subunit 4 17.78 4.89  8.75 1.22 -2.03 
210976_s_at PFKM phosphofructokinase, muscle 81.96 15.32  40.35 5.54 -2.03 
235716_at --- Transcribed locus 332.97 65.32  166.37 17.67 -2.00 
204293_at SGSH N-sulfoglucosamine sulfohydrolase (sulfamidase) 194.17 53.70  97.58 21.56 -1.99 
216985_s_at STX3 syntaxin 3 51.45 13.02  25.95 3.97 -1.98 
219349_s_at EXOC2 exocyst complex component 2 101.68 23.11  51.42 9.67 -1.98 
1555106_a_at CTDSPL2 CTD (carboxy-terminal domain, RNA polymerase II, 
polypeptide A) small phosphatase like 2 
26.86 7.11  13.73 1.94 -1.96 
228955_at --- Transcribed locus, weakly similar to NP_990560.1 very low 
density lipoprotein (VLDL)/vitellogenin receptor [Gallus 
40.02 9.18  20.53 7.21 -1.95 
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Affymetrix 
Probe set ID 
Gene symbol Gene name Mean fluorescence data ± SD (n = 3) FC 
   
T0  T14  
   
Mean ± SD  Mean ± SD  
gallus] 
233303_at UBE2D3 Ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, 
yeast) 
273.45 19.66  140.82 65.67 -1.94 
1560274_at WTAP /// 
LOC653150 
Wilms tumor 1 associated protein /// similar to Wilms tumor 1 
associated protein 
52.62 10.38  27.12 3.12 -1.94 
231989_s_at LOC23117 /// 
LOC440345 
KIAA0220-like protein /// hypothetical protein LOC440345 292.42 76.06  150.81 37.69 -1.94 
205997_at ADAM28 ADAM metallopeptidase domain 28 126.85 34.75  65.78 9.20 -1.93 
209383_at DDIT3 DNA-damage-inducible transcript 3 174.47 44.71  90.56 24.06 -1.93 
1560058_at LOC399900 hypothetical gene supported by AK093779 339.34 20.10  176.52 41.87 -1.92 
204286_s_at PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 253.10 50.92  132.15 15.69 -1.92 
201502_s_at NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha 
7748.34 1315.85  4050.19 295.88 -1.91 
AFFX-LysX-3_at --- --- 539.89 71.81  282.41 34.38 -1.91 
201531_at ZFP36 zinc finger protein 36, C3H type, homolog (mouse) 9825.24 2601.42  5168.46 1084.77 -1.90 
224572_s_at IRF2BP2 interferon regulatory factor 2 binding protein 2 647.26 90.70  342.18 87.24 -1.89 
230733_at MRCL3 Myosin regulatory light chain MRCL3 66.81 16.82  35.60 9.51 -1.88 
236213_at HNRPA3 Heterogeneous nuclear ribonucleoprotein A3 27.55 0.90  14.74 6.13 -1.87 
235369_at C14orf28 /// 
SYPL2 
chromosome 14 open reading frame 28 /// synaptophysin-like 
2 
30.51 5.59  16.38 3.36 -1.86 
239045_at ERN1 Endoplasmic reticulum to nucleus signalling 1 71.30 11.69  38.40 6.37 -1.86 
235088_at LOC201725 hypothetical protein LOC201725 41.74 7.39  22.48 0.88 -1.86 
1560486_at STXBP3 syntaxin binding protein 3 45.12 7.16  24.35 10.62 -1.85 
1556322_a_at TJAP1 Tight junction associated protein 1 (peripheral) 29.26 6.80  15.85 2.37 -1.85 
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Affymetrix 
Probe set ID 
Gene symbol Gene name Mean fluorescence data ± SD (n = 3) FC 
   
T0  T14  
   
Mean ± SD  Mean ± SD  
231165_at DDHD1 DDHD domain containing 1 173.88 36.18  94.29 14.80 -1.84 
219717_at C4orf30 chromosome 4 open reading frame 30 60.13 10.29  32.62 11.44 -1.84 
1554522_at CNNM2 cyclin M2 93.82 24.03  51.11 5.64 -1.84 
236752_at PKP4 Plakophilin 4 19.99 0.56  10.91 1.96 -1.83 
1558783_at WTAP Wilms tumor 1 associated protein 284.92 63.12  155.62 20.75 -1.83 
212225_at EIF1 eukaryotic translation initiation factor 1 1560.64 332.57  856.65 193.25 -1.82 
225484_at TSGA14 testis specific, 14 39.22 1.70  21.59 3.56 -1.82 
201918_at SLC25A36 Solute carrier family 25, member 36 271.19 52.37  149.28 49.07 -1.82 
232463_at CXYorf10 chromosome X and Y open reading frame 10 12.63 1.71  6.96 0.47 -1.81 
229676_at PAPD1 PAP associated domain containing 1 129.44 30.66  71.39 10.71 -1.81 
212655_at ZCCHC14 zinc finger, CCHC domain containing 14 86.83 22.21  47.91 7.45 -1.81 
201466_s_at JUN v-jun sarcoma virus 17 oncogene homolog (avian) 965.50 111.03  533.41 151.13 -1.81 
215850_s_at NDUFA5 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5, 
13kDa 
58.99 8.88  32.60 9.02 -1.81 
205045_at AKAP10 A kinase (PRKA) anchor protein 10 54.08 13.55  29.92 2.68 -1.81 
211272_s_at DGKA diacylglycerol kinase, alpha 80kDa 122.76 31.89  68.17 5.75 -1.80 
226663_at ANKRD10 ankyrin repeat domain 10 395.88 29.23  219.94 31.42 -1.80 
218401_s_at ZNF281 zinc finger protein 281 640.56 115.35  357.28 23.43 -1.79 
221986_s_at KLHL24 kelch-like 24 (Drosophila) 199.67 31.82  111.78 17.09 -1.79 
212434_at GRPEL1 GrpE-like 1, mitochondrial (E. coli) 383.96 93.78  215.12 18.12 -1.78 
227501_at WSB1 WD repeat and SOCS box-containing 1 193.85 50.27  109.25 12.25 -1.77 
215300_s_at FMO5 flavin containing monooxygenase 5 52.37 4.76  29.70 0.81 -1.76 
202972_s_at FAM13A1 family with sequence similarity 13, member A1 66.24 13.43  37.62 1.80 -1.76 
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Affymetrix 
Probe set ID 
Gene symbol Gene name Mean fluorescence data ± SD (n = 3) FC 
   
T0  T14  
   
Mean ± SD  Mean ± SD  
201727_s_at ELAVL1 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 
(Hu antigen R) 
254.36 59.47  144.65 16.08 -1.76 
243134_at LOC440309 Hypothetical LOC440309 511.53 28.94  290.98 10.40 -1.76 
244778_x_at GPIAP1 GPI-anchored membrane protein 1 138.32 15.01  78.69 21.77 -1.76 
222669_s_at SBDS Shwachman-Bodian-Diamond syndrome 436.75 109.04  248.67 26.22 -1.76 
219961_s_at C20orf19 chromosome 20 open reading frame 19 57.71 4.93  32.90 4.64 -1.75 
227290_at --- CDNA FLJ13598 fis, clone PLACE1009921 161.52 29.01  92.42 28.72 -1.75 
202723_s_at FOXO1A forkhead box O1A (rhabdomyosarcoma) 170.03 34.37  97.68 11.02 -1.74 
225408_at MBP myelin basic protein 126.71 33.02  72.83 3.98 -1.74 
227762_at --- Transcribed locus 63.03 16.30  36.35 2.43 -1.73 
226735_at FLJ90013 hypothetical protein FLJ90013 96.61 20.84  55.91 10.34 -1.73 
243857_at MORF4L2 Mortality factor 4 like 2 99.99 9.79  57.90 7.80 -1.73 
203414_at MMD monocyte to macrophage differentiation-associated 146.68 30.03  85.02 19.30 -1.73 
214805_at EIF4A1 Eukaryotic translation initiation factor 4A, isoform 1 1041.38 164.23  604.32 41.72 -1.72 
206877_at MXD1 MAX dimerization protein 1 93.68 17.53  54.37 13.46 -1.72 
226644_at MIB2 mindbomb homolog 2 (Drosophila) 99.74 4.25  57.94 4.61 -1.72 
219634_at CHST11 carbohydrate (chondroitin 4) sulfotransferase 11 479.71 88.50  279.64 25.39 -1.72 
1555334_s_at SLC30A5 solute carrier family 30 (zinc transporter), member 5 47.87 7.61  28.00 1.96 -1.71 
218374_s_at C12orf4 chromosome 12 open reading frame 4 61.63 14.74  36.12 2.96 -1.71 
219599_at PRO1843 hypothetical protein PRO1843 210.26 27.93  124.02 18.83 -1.70 
206059_at ZNF91 zinc finger protein 91 283.17 52.13  167.71 6.43 -1.69 
223430_at SNF1LK2 SNF1-like kinase 2 118.15 13.48  70.05 10.79 -1.69 
227620_at --- --- 111.10 18.45  66.04 16.28 -1.68 
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Affymetrix 
Probe set ID 
Gene symbol Gene name Mean fluorescence data ± SD (n = 3) FC 
   
T0  T14  
   
Mean ± SD  Mean ± SD  
238156_at RPS6 Ribosomal protein S6 453.67 70.80  269.78 8.25 -1.68 
202773_s_at SFRS8 splicing factor, arginine/serine-rich 8 (suppressor-of-white-
apricot homolog, Drosophila) 
100.34 20.94  59.75 6.26 -1.68 
212912_at RPS6KA2 ribosomal protein S6 kinase, 90kDa, polypeptide 2 9.19 0.94  5.48 0.60 -1.68 
209287_s_at CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 437.88 95.03  261.12 53.24 -1.68 
214318_s_at FRY furry homolog (Drosophila) 42.76 9.07  25.54 5.10 -1.67 
201464_x_at JUN v-jun sarcoma virus 17 oncogene homolog (avian) 2478.03 219.98  1482.79 264.52 -1.67 
1554015_a_at CHD2 chromodomain helicase DNA binding protein 2 62.09 7.08  37.21 5.46 -1.67 
236836_at TBCA Tubulin-specific chaperone a 158.44 13.33  95.18 23.82 -1.66 
225963_at KLHDC5 kelch domain containing 5 78.15 8.06  46.99 4.38 -1.66 
210512_s_at VEGF vascular endothelial growth factor 396.72 69.92  238.80 9.45 -1.66 
209053_s_at WHSC1 Wolf-Hirschhorn syndrome candidate 1 49.68 9.19  29.97 4.91 -1.66 
201580_s_at TXNDC13 thioredoxin domain containing 13 298.28 68.07  179.97 0.95 -1.66 
1557263_s_at --- CDNA FLJ35536 fis, clone SPLEN2002451 236.85 50.22  143.12 25.77 -1.65 
209349_at RAD50 RAD50 homolog (S. cerevisiae) 59.71 14.05  36.19 3.93 -1.65 
218051_s_at NT5DC2 5'-nucleotidase domain containing 2 21.30 3.95  12.92 1.19 -1.65 
217246_s_at DIAPH2 diaphanous homolog 2 (Drosophila) 24.47 4.56  14.89 1.26 -1.64 
214960_at API5 apoptosis inhibitor 5 91.81 16.89  55.91 5.59 -1.64 
202726_at LIG1 ligase I, DNA, ATP-dependent 14.38 0.46  8.76 2.25 -1.64 
230270_at PRPF38B PRP38 pre-mRNA processing factor 38 (yeast) domain 
containing B 
502.76 64.95  306.53 77.77 -1.64 
1555905_a_at C3orf23 chromosome 3 open reading frame 23 66.50 7.10  40.58 4.04 -1.64 
1556007_s_at CSNK1A1 Casein kinase 1, alpha 1 240.85 31.93  146.99 13.76 -1.64 
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Affymetrix 
Probe set ID 
Gene symbol Gene name Mean fluorescence data ± SD (n = 3) FC 
   
T0  T14  
   
Mean ± SD  Mean ± SD  
228702_at FLJ43663 /// 
LOC641825 
/// 
LOC647017 
hypothetical protein FLJ43663 /// hypothetical protein 
LOC641825 /// hypothetical protein LOC647017 
76.10 12.06  46.46 8.11 -1.64 
205704_s_at ATP6V0A2 ATPase, H+ transporting, lysosomal V0 subunit a2 32.87 5.97  20.08 0.23 -1.64 
226679_at SLC26A11 solute carrier family 26, member 11 307.71 6.39  188.49 50.78 -1.63 
212677_s_at CEP68 centrosomal protein 68kDa 69.71 10.76  42.74 9.80 -1.63 
235745_at ERN1 endoplasmic reticulum to nucleus signalling 1 84.00 10.72  51.54 3.95 -1.63 
239963_at --- Transcribed locus 36.93 6.37  22.67 5.91 -1.63 
231357_at CLEC12B C-type lectin domain family 12 member B 74.77 10.88  46.18 13.92 -1.62 
213459_at RPL37A ribosomal protein L37a 109.69 14.35  67.78 4.13 -1.62 
212960_at TBC1D9 TBC1 domain family, member 9 (with GRAM domain) 173.99 27.30  107.59 19.40 -1.62 
232280_at SLC25A29 Solute carrier family 25, member 29 29.16 4.72  18.05 0.42 -1.62 
214931_s_at SRPK2 SFRS protein kinase 2 84.91 17.46  52.59 6.38 -1.61 
227113_at ADHFE1 alcohol dehydrogenase, iron containing, 1 98.89 14.62  61.40 6.40 -1.61 
204233_s_at CHKA choline kinase alpha 79.48 14.32  49.38 2.08 -1.61 
239734_at LOC401320 Hypothetical LOC401320 57.51 2.39  35.82 8.59 -1.61 
211578_s_at RPS6KB1 ribosomal protein S6 kinase, 70kDa, polypeptide 1 82.34 9.04  51.30 3.68 -1.61 
209336_at PWP2H PWP2 periodic tryptophan protein homolog (yeast) 115.66 18.47  72.06 13.92 -1.61 
203803_at PCYOX1 prenylcysteine oxidase 1 48.92 4.38  30.50 8.39 -1.60 
218918_at MAN1C1 mannosidase, alpha, class 1C, member 1 121.81 11.07  76.06 12.00 -1.60 
33494_at ETFDH electron-transferring-flavoprotein dehydrogenase 111.81 14.68  70.11 6.44 -1.59 
1564274_at C9orf47 chromosome 9 open reading frame 47 16.94 3.50  10.65 0.83 -1.59 
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Affymetrix 
Probe set ID 
Gene symbol Gene name Mean fluorescence data ± SD (n = 3) FC 
   
T0  T14  
   
Mean ± SD  Mean ± SD  
225896_at M-RIP Myosin phosphatase-Rho interacting protein 49.05 5.98  30.89 6.65 -1.59 
220408_x_at FAM48A family with sequence similarity 48, member A 232.33 38.93  146.40 13.54 -1.59 
223171_at DYM dymeclin 259.99 58.73  163.90 4.07 -1.59 
209876_at GIT2 G protein-coupled receptor kinase interactor 2 307.62 53.10  194.13 36.21 -1.58 
209294_x_at TNFRSF10B tumor necrosis factor receptor superfamily, member 10b 48.56 2.71  30.71 4.57 -1.58 
220702_at --- --- 62.30 12.63  39.51 2.07 -1.58 
231630_at FLJ16341 Hypothetical gene supported by AK122786 13.35 2.47  8.47 0.58 -1.58 
230099_at --- Transcribed locus 381.13 80.53  241.98 9.74 -1.58 
219437_s_at ANKRD11 ankyrin repeat domain 11 284.34 25.71  180.54 28.45 -1.57 
226533_at --- --- 72.93 2.31  46.37 10.76 -1.57 
213211_s_at TAF6L TAF6-like RNA polymerase II, p300/CBP-associated factor 
(PCAF)-associated factor, 65kDa 
29.60 6.25  18.82 2.33 -1.57 
211938_at EIF4B eukaryotic translation initiation factor 4B 2103.11 275.84  1339.42 362.38 -1.57 
201810_s_at SH3BP5 SH3-domain binding protein 5 (BTK-associated) 367.07 59.30  233.88 32.97 -1.57 
241425_at NUPL1 Nucleoporin like 1 160.72 17.53  102.50 20.63 -1.57 
35626_at SGSH N-sulfoglucosamine sulfohydrolase (sulfamidase) 776.86 127.80  495.97 93.33 -1.57 
222147_s_at ACTR5 ARP5 actin-related protein 5 homolog (yeast) 44.11 7.11  28.17 5.87 -1.57 
226688_at C3orf23 chromosome 3 open reading frame 23 51.98 3.47  33.26 3.48 -1.56 
222427_s_at LARS leucyl-tRNA synthetase 550.35 115.62  352.48 19.25 -1.56 
229246_at FLJ44342 hypothetical protein LOC645460 85.85 16.30  55.00 4.91 -1.56 
230050_at BTBD14A BTB (POZ) domain containing 14A 78.08 1.34  50.12 12.73 -1.56 
212227_x_at EIF1 eukaryotic translation initiation factor 1 11007.74 1811.55  7077.43 1189.29 -1.56 
233563_s_at CPSF3L cleavage and polyadenylation specific factor 3-like 234.47 22.74  150.76 19.07 -1.56 
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Affymetrix 
Probe set ID 
Gene symbol Gene name Mean fluorescence data ± SD (n = 3) FC 
   
T0  T14  
   
Mean ± SD  Mean ± SD  
238736_at REV3L REV3-like, catalytic subunit of DNA polymerase zeta (yeast) 589.15 108.94  379.71 51.07 -1.55 
203198_at CDK9 cyclin-dependent kinase 9 (CDC2-related kinase) 227.36 29.32  146.54 10.90 -1.55 
202973_x_at FAM13A1 family with sequence similarity 13, member A1 845.30 133.28  545.05 120.03 -1.55 
202469_s_at CPSF6 cleavage and polyadenylation specific factor 6, 68kDa 632.31 112.45  407.73 38.69 -1.55 
242255_at WDR37 WD repeat domain 37 52.68 8.62  34.02 3.07 -1.55 
201433_s_at PTDSS1 phosphatidylserine synthase 1 1358.81 213.82  877.91 135.36 -1.55 
217100_s_at UBXD7 UBX domain containing 7 140.86 11.65  91.05 16.88 -1.55 
227056_at KIAA0141 KIAA0141 337.61 53.05  218.36 19.58 -1.55 
227946_at OSBPL7 oxysterol binding protein-like 7 74.51 12.62  48.19 1.14 -1.55 
238987_at B4GALT1 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 1 
446.95 31.51  289.48 65.69 -1.54 
218177_at CHMP1B chromatin modifying protein 1B 317.34 62.80  205.60 24.68 -1.54 
211769_x_at SERINC3 serine incorporator 3 /// serine incorporator 3 194.84 37.57  126.34 9.21 -1.54 
202021_x_at EIF1 eukaryotic translation initiation factor 1 11117.73 1379.83  7216.36 999.49 -1.54 
203245_s_at FLJ35348 FLJ35348 32.51 4.24  21.12 3.77 -1.54 
222824_at SEC61A2 Sec61 alpha 2 subunit (S. cerevisiae) 121.71 14.20  79.09 12.20 -1.54 
238455_at --- CDNA FLJ45742 fis, clone KIDNE2016327 248.53 22.51  161.95 47.80 -1.53 
223129_x_at MYLIP myosin regulatory light chain interacting protein 231.14 17.84  150.63 41.90 -1.53 
209191_at TUBB6 tubulin, beta 6 238.01 14.13  155.25 36.17 -1.53 
200779_at ATF4 activating transcription factor 4 (tax-responsive enhancer 
element B67) 
2806.53 281.64  1830.90 174.43 -1.53 
233647_s_at CDADC1 cytidine and dCMP deaminase domain containing 1 99.43 14.92  64.96 7.77 -1.53 
212130_x_at EIF1 eukaryotic translation initiation factor 1 10499.00 1324.06  6870.47 1152.71 -1.53 
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Affymetrix 
Probe set ID 
Gene symbol Gene name Mean fluorescence data ± SD (n = 3) FC 
   
T0  T14  
   
Mean ± SD  Mean ± SD  
1554155_at MCPH1 microcephaly, primary autosomal recessive 1 41.97 7.11  27.51 2.29 -1.53 
225588_s_at TMEM129 transmembrane protein 129 154.93 11.70  101.55 26.50 -1.53 
222303_at --- --- 684.77 31.29  448.95 65.91 -1.53 
231431_s_at LOC388114 
/// 
LOC649557 
hypothetical LOC388114 /// hypothetical protein LOC649557 272.64 47.72  178.89 19.53 -1.52 
214482_at ZBTB25 zinc finger and BTB domain containing 25 73.63 4.74  48.33 4.76 -1.52 
228174_at GOLGA1 Golgi autoantigen, golgin subfamily a, 1 35.72 4.75  23.50 5.80 -1.52 
212508_at MOAP1 modulator of apoptosis 1 1096.57 175.42  723.02 85.48 -1.52 
226030_at ACADSB acyl-Coenzyme A dehydrogenase, short/branched chain 86.02 11.61  56.75 7.99 -1.52 
240106_at GNPTAB N-acetylglucosamine-1-phosphate transferase, alpha and 
beta subunits 
41.49 6.74  27.40 4.31 -1.51 
225993_at EARS2 glutamyl-tRNA synthetase 2 (mitochondrial)(putative) 16.29 2.73  10.76 0.93 -1.51 
235463_s_at LASS6 LAG1 longevity assurance homolog 6 (S. cerevisiae) 84.62 4.48  55.94 14.01 -1.51 
204313_s_at CREB1 cAMP responsive element binding protein 1 932.93 94.18  618.42 71.64 -1.51 
223266_at ALS2CR2 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, 
candidate 2 
144.29 15.46  95.66 3.03 -1.51 
201473_at JUNB jun B proto-oncogene 4874.58 515.01  3234.97 781.83 -1.51 
1567080_s_at CLN6 ceroid-lipofuscinosis, neuronal 6, late infantile, variant 90.44 8.33  60.05 2.42 -1.51 
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Table 5 Mean fluorescence data and fold change values of target genes from microarray and qRT-PCR experiments 
in monocytes of Q10H2-supplemented subjects 
Gene Gene name      Mean fluorescence data ± SD 
                           (n = 3) 
FC 
Microarray 
T0 vs. T14 
qRT-PCR 
(verifications) 
  T0 T14   Technical 
(n = 3) 
Biological 
(n = 9) 
Inflammation/ 
Immune 
response 
 
      
TNFα tumor necrosis factor alpha 158.26 ± 92.90 36.66 ± 11.52  -4.3* -4.0 ± 0.2** -2.6 ± 0.1** 
CXCL2 chemokine (C-X-C motif) 
ligand 2 
1149.75 ± 865.42 93.01 ± 29.81  -8.8*# -20.9 ± 0.2** -3.6 ± 0.1*** 
IL8 interleukin 8 1525.09 ± 1372.25 55.87 ± 12.92  -21.3*# -6.3 ± 0.7* -1.3 ± 0.5 
CCL3 chemokine (C-C motif) 
ligand 3 
4591.46 ± 2758.68 658.29 ± 390.95  -7.0* -2.5 ± 0.2** -1.7 ± 0.1* 
GIMAP7 GTPase, IMAP family 
member 7 
1468.59 ± 1013.58 3738.86 ± 176.80  2.6* 1.8 ± 0.1* 1.4 ± 0.1* 
Apoptosis        
NR4A2 (NURR1) nuclear receptor subfamily 
4, group A, member 2 
664.26 ± 412.31 100.46 ± 37.53  -5.2*# -6.4 ± 1.1* -2.7 ± 0.5* 
BRE brain and reproductive 
organ-expressed 
94.61 ± 8.87 14.32 ± 5.31  -6.6*** -1.8 ± 0.1* -1.5 ± 
0.1*** 
miR21 microRNA 21 630.29 ± 229.14 1540.31 ± 285.74  2.4* 1.6 ± 0.1*** 1.1 ± 0.1 
PMAIP1 Phorbol-12-myristate-13-
acetate-induced protein 1 
1270.73 ± 35.11 577.55 ± 106.44  -2.2* -1.5 ± 0.1* -1.9 ± 0.2** 
#
 Mean of > 2 probe set IDs, p < 0.05; * T0 vs. T14, p < 0.05; ** T0 vs. T14, p < 0.01; *** T0 vs. T14, p < 0.001  
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Table 6 Release of pro-inflammatory markers in serum 
 samples of study subjects before (T0) and after 
 (T14) Q10H2 supplementation 
Parameters T0 T14 
TNFα (pg/ml) 139.37 ± 122.24 144.60 ± 140.00 
CXCL2 (pg/ml) 251.97 ± 68.78 252.02 ± 69.47 
MCP-1 (ng/ml) 184.88 ± 108.55 183.23 ± 107.59 
CRP (mg/dl) 0.30 ± 0.01 0.31 ± 0.05 
Data are described as means + SD 
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Table 7 Release of TNFα and MCP-1 in ex vivo LPS stimulated whole blood 
samples of study subjects before (T0) and after (T14) Q10H2 
supplementation 
 T0  T14 
 -LPS +LPS +LPS/ 
-LPS 
 -LPS +LPS +LPS/ 
-LPS 
TNFα  
(pg/ml) 
79.17 
± 30.53 
2091.28 
± 648.81 
30.43 
± 19.13 
 86.65 
 ± 31.65 
2571.12 
 ± 908.45 
31.86 
 ± 12.44 
MCP-1  
(ng/ml) 
90.84 
± 41.36 
159.66 
± 57.49 
1.92 
± 0.72 
 94.62 
 ± 41.39 
160.66 
 ± 59.64 
1.88 
 ± 0.86 
Data are described as means + SD 
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Table 8 Serum levels of lipid parameters  
before (T0) and after (T14) Q10H2 supplementation 
Parameters T0 T14 
Cholesterol (mg/dl) 166.09 ± 29.79 163.85 ± 27.85 
HDL cholesterol (mg/dl) 51.13 ± 12.93 51.3 ± 11.9 
LDL cholesterol (mg/dl) 95.51 ± 28.89 90.60 ± 27.21* 
oxLDL (U/ml) 20.62 ± 14.67 20.43 ± 14.46 
Triglycerides (mg/dl) 97.40 ± 49.04 112.32 ± 73.13 
*
 T0 vs. T14, p < 0.05; Data are described as means + SD 
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Table 9 Blood parameters of study subjects before (T0) and after 2-week 
supplementation period (T14) with Q10H2 (n = 53) 
 T0 T14 
Leukocytes 5.65 ± 1.43 5.74 ± 1.28 
Erythrocytes 4.95 ± 0.29 4.89 ± 0.31* 
Hemoglobin 15.16 ± 0.82 15.04 ± 0.85 
Hematocrit 44.48 ± 2.36 43.78 ± 2.40** 
MCV1 89.82 ± 2.87 89.76 ± 2.78 
MCH2 30.62 ± 1.12 30.82 ± 1.17* 
MCHC3 34.09 ± 0.53 34.33 ± 0.53* 
Reticulocytes 10.94 ± 3.03 12.09 ± 2.46*** 
Data are described as means ± SD 
*
 T0 vs. T14, p < 0.05  
**
 T0 vs. T14, p < 0.01  
***
 T0 vs. T14, p < 0.001  
1Mean corpuscular volume 
2Mean corpuscular haemoglobin 
3Mean corpuscular haemoglobin concentration 
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T0 T14 T42
0.00
0.25
0.50
0.75
1.00
1.25
***
**
***
B
CX
CL
2 
m
R
N
A
 
le
v
el
(re
la
te
d 
to
 
T 0
)
T0 T14 T42
0.00
0.25
0.50
0.75
1.00
1.25
**
**
*A
TN
Fa
lp
ha
 
m
R
N
A
 
le
v
el
(re
la
te
d 
to
 
T 0
)
T0 T14 T42
0
1
2
*
E
GI
M
AP
7 
m
RN
A 
le
v
el
(re
la
te
d 
to
 
T 0
)
T0 T14 T42
0.0
0.5
1.0
1.5 * ***
D
NR
4A
2 
m
RN
A 
le
v
el
(re
la
te
d 
to
 
T 0
)
T0 T14 T42
0.00
0.25
0.50
0.75
1.00
1.25 *** *
F
BR
E 
m
R
NA
 
le
ve
l
(re
la
te
d 
to
 
T 0
)
T0 T14 T42
0.00
0.25
0.50
0.75
1.00
1.25
*
***C
CC
L3
 
m
RN
A 
le
v
e
l
(re
la
te
d 
to
 
T 0
)
T0 T14 T42
0.00
0.25
0.50
0.75
1.00
1.25 **
G
PM
A
IP
1 
m
R
NA
 
le
v
el
(re
la
te
d 
to
 
T 0
)
  52 
Figure 3 
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Figure 4 
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Figure 5 
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